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ABSTRACT 
UNIVERSITY OF TURKU 
Department of Chemistry, Faculty of Mathematics and Natural Sciences 
LEISVUORI, ANNA: Prodrug Strategies of Antiviral Nucleotides: Studies on 
Enzymatically and Thermally Removable Phosphate Protecting Groups 
Doctoral thesis, 139 p. 
Laboratory of Organic Chemistry and Chemical Biology 
September 2015 
Antiviral nucleosides are compounds that are used against viruses, such as 
human immunodeficiency virus (HIV) and hepatitis C virus (HCV). To act as 
therapeutic agent, the antiviral nucleoside needs to be phosphorylated to 
nucleotide in the body in three consecutive phosphorylation steps by cellular or 
viral enzymes. The first phosphorylation to the nucleoside monophosphate is 
often inefficient and leads to poor antiviral activity. The antiviral efficacy can be 
improved by applying a prodrug strategy and delivering the antiviral nucleoside 
directly as its monophosphate. In prodrug strategies of antiviral nucleotides, the 
negative charges on the phosphate moiety are temporarily masked with 
protecting groups. Once inside the cell, the protecting groups are removed by 
enzymatic or chemical processes. Many prodrug strategies apply biodegradable 
protecting groups, the removal of which is triggered by esterase enzymes. 
Several studies have, however, demonstrated that the removal rate of the second 
and subsequent esterase labile protecting groups significantly slows down after 
the first protecting group is removed due to the negative charge on the 
phosphodiester intermediate, which disturbs the catalytic site of the enzyme. In 
this thesis, esterase labile protecting group strategies where the issue of 
retardation could be avoided were studied.  
Prodrug candidates of antiviral nucleotides were synthesized and kinetic studies 
on the chemical and enzymatic stability were carried out. In the synthesized 
compounds, the second protecting group is cleaved from the monophosphate by 
some other mechanism than esterase triggered activation or the structure of the 
prodrug requires only one protecting group. In addition, esterase labile protecting 
group which is additionally thermally removable was studied. This protecting 
group was cleaved from oligomeric phosphodiesters both enzymatically and 
thermally and seems most attractive of the studied phosphate protecting groups. 
However, the rate of the thermal removal still is too slow to allow efficient 
protection of longer oligonucleotides and needs optimization. 




Kemian laitos, Matemaattis-luonnontieteellinen tiedekunta 
LEISVUORI, ANNA: Antiviraalisten nukleotidien aihiolääkestrategiat: 
entsyymin ja lämpötilan vaikutuksesta irtoavat fosfaatin suojaryhmät 
Väitöskirja, 139 s. 
Orgaanisen kemian ja kemiallisen biologian laboratorio 
Syyskuu 2015 
Antiviraaliset nukleosidit ovat yhdisteitä, joita voidaan käyttää esimerkiksi HI-
virusta (human immunodeficiency virus) ja hepatiitti C virusta vastaan. Jotta 
antiviraalinen nukleosidi voi toimia lääkeaineena, se on fosforyloitava 
elimistössä nukleotidiksi viruksen tai solun entsyymien avulla kolmessa 
peräkkäisessä fosforylointireaktiossa. Ensimmäinen fosforylointireaktio 
nukleosidimonofosfaatiksi on kuitenkin usein tehoton ja johtaa heikkoon 
antiviraaliseen aktiivisuuteen. Antiviraalista vaikutusta voidaan tehostaa 
käyttämällä aihiolääkestrategiaa ja annostelemalla antiviraalinen nukleosidi 
suoraan monofosfaattina. Antiviraalisten nukleotidien aihiolääkestrategioissa 
fosfaatin negatiiviset varaukset naamioidaan suojaryhmillä, jotka irtoavat solun 
sisällä entsymaattisten tai kemiallisten prosessien avulla. Monissa 
suojaryhmästrategioissa käytetään biohajoavia suojaryhmiä, joiden irtoaminen 
tapahtuu esteraasientsyymien avulla. Useat tutkimukset ovat kuitenkin 
osoittaneet, että ensimmäisen suojaryhmän irrottua seuraavien suojaryhmien 
irtoaminen hidastuu merkittävästi johtuen fosfodiesterivälituotteen negatiivisesta 
varauksesta, joka häiritsee entsyymin katalyyttistä keskusta. Tässä väitöskirjassa 
tutkittiin esteraasien avulla irtoavia suojaryhmästrategioita, joissa suojaryhmien 
irtoamisen hidastuminen voitaisiin välttää. 
Työssä valmistettiin antiviraalisten nukleotidien aihiolääke-ehdokkaita ja 
tutkittiin niiden suojaryhmien entsymaattisen ja kemiallisen irtoamisen 
kinetiikkaa. Valmistetuissa yhdisteissä toinen monofosfaatin suojaryhmistä irtoaa 
jollain muulla kuin esteraasin aktivoimalla mekanismilla tai yhdisteen rakenne 
vaatii ainoastaan yhden suojaryhmän. Lisäksi tutkittiin esteraasin avulla irtoavaa 
suojaryhmää, joka irtoaa myös lämpötilan vaikutuksesta. Tämä suojaryhmä irtosi 
oligomeerisista fosfodiestereistä niin entsymaattisesti kuin lämpötilan 
vaikutuksestakin ja oli tutkituista fosfaatin suojaryhmistä lupaavin. Lämpötilan 
aiheuttama suojaryhmän irtoaminen on kuitenkin liian hidas ja vaatii optimointia, 
jotta sitä voitaisiin käyttää pidempien oligonukleotidien suojaamiseen. 
Asiasanat: antiviraalinen, nukleotidi, aihiolääke, suojaryhmä, biohajoava
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1 INTRODUCTION 
1.1 Discovery of antiviral nucleosides 
For being just tiny simple particles, made up only of genetic material coated with 
protein, viruses cause a full spectrum of diseases from common cold to highly 
severe states, such as cancer. Vaccination is an effective method in preventing 
many viral infections. National vaccination programs give protection against 
childhood diseases, such as polio or measles, and systematic worldwide 
vaccination against smallpox, a contagious disease caused by variola virus, has 
even led to eradication of the virus in 1980.
1
 Vaccines contain inactivated or 
weakened viruses or viral structural proteins, which do not cause infection, but 
stimulate the immune system to produce antigens and memory cells and thus, 
lead to an artificially acquired immunity against a virus. Vaccination is a 
preventive action and is not usually effective on already infected patients or 
patients with weakened immune response. In addition, it appears difficult to 
develop a vaccine for viruses, such as human immunodeficiency virus (HIV) and 
hepatitis C virus (HCV), with high genetic variability, because the composition 
of the immune system triggering glycoproteins present on the viral surface is so 
variable. Accordingly, antiviral therapies based on other mechanisms are needed. 
Viral infections can be treated with antiviral agents, compounds that inhibit the 
development of new virus particles in the host cell. Most of the antiviral agents 
on the market today are targeted against HIV, hepatitis B and C viruses, herpes 
viruses and influenza viruses. Nucleoside analogs constitute an important class of 
antiviral agents. 
The utilization of nucleosides as antiviral agents dates back to early 1960’s when 




 (Figure 1), were 
launched for the treatment of herpetic keratitis. Due to poor selectivity for virus 
infected cells, the compounds were too toxic to be taken internally and were only 
licensed for external use. The actual mechanism of viral inhibition was at that 
time not known. A finding that greatly improved the understanding of inhibition 
mechanisms of antiviral nucleosides was the discovery of acyclovir
5
 (ACV) as a 
selective inhibitor of herpes simplex virus (HSV). ACV is phosphorylated only 
by viral kinase, not by the kinases of the host cell, and it, hence, acts only in virus 
infected cells. The recognition of HIV as the cause of acquired immune 
deficiency syndrome
6
 (AIDS) in 1983 truly started the extensive exploration of 
antiviral agents and in 1987 the first anti-HIV nucleoside, azidothymidine
7
 
(AZT), was approved. Over the past two decades, the treatment of HIV has 
evolved from taking a handful of pills a day to a one pill a day regimen. The 
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research to find new and more selective antiviral agents is ongoing. The 
increased mobility of people brings new challenges to the development of 
antiviral agents, as rare or new severe viral diseases are more easily spread 
around the world than ever before, the latest example being the Ebola virus 
outbreak in western Africa in 2014.
 
 
Figure 1 Structures of few key antiviral nucleosides. 
There are currently 26 approved antiviral nucleosides and nucleotides for the 
treatment of viral infections, the majority of them being aimed at treatment of 
HIV and HSV.
8
 The antiviral activity of nucleosides can be further improved by 
prodrug strategies, where the antiviral nucleoside is administered as its 
monophosphate, which is masked with appropriate phosphate protecting groups. 
Figure 2 represents three nucleoside derived prodrugs. Adefovir dipivoxil
9
 (trade 
name Hepsera) has been used to the treat hepatitis B virus (HBV) infected 
patients since 2002.  Tenofovir disoproxil fumarate
10
 (trade name Viread) was 
accepted for the treatment of HIV in 2001 and in 2008 also for the treatment of 
HBV. The latest antiviral agent on the market is sofosbuvir
11
  (trade name 
Sovaldi), which was accepted by the US Food and Drug Administration in 
December 2013. The standard treatment for HCV has, for more than a decade, 
been nucleoside analog ribavirin in combination with injections of pegylated 
interferon-,
12
 but sofosbuvir can be used to treat HCV without interferon- 
injections.  
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Figure 2 Approved prodrugs of antiviral nucleoside phosphates and phosphonates. 
1.2 Antiviral nucleosides as drugs 
1.2.1 Viral life cycle and targets for drug intervention 
Viruses are small, non-cellular particles, consisting of genetic material coated by 
a protein capsid. The genetic material can consist of ribonucleic acid (RNA) or 
deoxyribonucleic acid (DNA) and it can be single or double stranded, depending 
on the virus. In some cases, the viral nucleocapsid also includes a few essential 
viral enzymes or is additionally surrounded by a membranous layer of lipids and 
glycoproteins. Viruses are obligate parasites: they don’t have own cellular 
mechanisms and their reproduction is dependent on a host cell. Viruses are 
capable of infecting animal, plant or bacterial cells with their genetic material 
and exploiting the host cell metabolism to produce multiple copies of the virion.  
The life cycle of viruses can be divided into separate steps which are all, in 
principle, potential targets for drug intervention.
13,14
 The replicative cycle varies 
to some extent depending on the virus and the nature of its genetic material, but 
the following steps can be roughly separated for all viruses: adsorption of the 
virus to the host cell surface, penetration into the cell and uncoating of the 
genetic material, replication and transcription by the host-cell machinery, 
synthesis and assembly of nucleocapsids, and finally, departure of the mature 
virions from the host cell.
 
The steps, which are carried out by the host cell 
enzymes, closely resemble the normal cellular processes. Antiviral agents 
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interfering with such processes most likely lead to cytotoxicity, since the 
compounds are not capable of distinguishing virus infected cells from the healthy 
ones. The best targets for antiviral agents are the most divergent steps requiring, 
in many cases, viral enzymes. This improves the selectivity of the antiviral 
agents for virus infected cells.
 
The viral life cycles of HIV and HCV are represented in Figures 3 and 4, 
respectively. These are both RNA viruses, the HIV genome constituting of two 
and the HCV genome of one positive-sense single-stranded RNA molecule.  HIV 
is a retrovirus and the host cell nucleus is involved in the replicative cycle. CD4 
glycoproteins on the surface of T-helper cells act as receptors for HIV. Once 
inside the cell, double stranded DNA is produced from the viral RNA by viral 
reverse transcriptase enzyme and the DNA is then integrated to the host cell 
genome by viral integrase, forming a so called provirus, which is then further 
transcribed. In contrast to HIV, the viral RNA of HCV is translated and 





Figure 3 The HIV replicative cycle in T-helper cell. (ER = Endoplasmic 
reticulum) 
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Figure 4 The HCV replicative cycle in hepatocyte. (ER = Endoplasmic reticulum) 
The anti-HIV agents currently in use or in clinical trials include co-receptor 
antagonists (inhibition of adsorption), fusion inhibitors, reverse transcriptase 
inhibitors, integrase inhibitors and protease inhibitors. The antiviral nucleoside 
and nucleotide analogs act as reverse transcriptase (also called RNA-dependent 
DNA polymerase) inhibitors. The targets for anti-HCV agents include RNA 
replicase (RNA-dependent RNA polymerase) inhibitors and protease inhibitors, 
the nucleoside and nucleotide analogs belonging to the first mentioned class.
15,16
  
Both HIV and HCV mutate readily because of short life-cycle and lack of 
proofreading enzymes. The viruses can develop resistance to antiviral drugs, but 
with combination therapy, by using more than one antiviral agent at a time, the 
chance for resistance development can be minimized. Since 1996 HIV infection 
has been treated with the so called highly active antiviral therapy (HAART) 
where at least three HIV inhibitors are combined into a single pill. For example, 
Atripla combines three antiviral agents: tenofovir disoproxil fumarate (a 
nucleotide reverse transcriptase inhibitor), emtricitabine (a nucleoside reverse 





The treatment of HCV aims to more precise regimens too. Combination of 
ribavirin and pegylated interferon-, which was long the standard of care, has 
variable efficiency to HCV depending on the genotype of the virus.  Interferons 
act usually as immunomodulatory agents, but in the combination therapy with 
ribavirin, their role seems to be different. Interferon acts as the antiviral agent, 
targeted at a phosphoprotein encoded by the NS5A gene of HCV, and ribavirin is 
the immunomodulatory agent by acting as inhibitor of inosine monophosphate 
dehydrogenase, and thus affecting the biosynthesis and levels of guanosine 
triphosphate in the cell.
18
 Only 40-50% of patients with HCV genotype 1 achieve 
sustained virological response after 48 weeks treatment, while with genotypes 2 
and 3 the rate can be as high as 75%.
19
  Of the six genotypes of HCV, genotype 1 
has been the most difficult one to treat and it also is the most common genotype 
in western countries. The treatment options for HCV are evolving with 
accelerated speed due to the new direct-acting antivirals (DAA), which are 
targeted to a specific step in the HCV life cycle, as has been the case with anti-
HIV agents already for years.
20 
 Sofosbuvir has opened up the way towards all-
oral treatment of HCV and several more direct-acting antivirals, which are in 




The use of more than one antiviral nucleoside at the same time can cause drug-
drug interactions and thus the different combinations have to be thoroughly 
evaluated. For instance, AZT (Figure 1) is able to inhibit the phosphorylation of 
stavudine (d4T, Figure 1) in vitro.
22
 The development of drug resistance may be 
reduced by optimization of the drug delivery. If the drug reaches its target 
efficiently, the dosage may be lowered and the duration of treatment can be 
shortened. In addition to delivering the antiviral nucleosides as their 
monophosphates, prodrug strategies can also be used to achieve site-selective 
delivery and thus improve the efficiency of the drug.  
1.2.2 Structure of antiviral nucleosides 
Antiviral nucleosides are structural analogs of natural ribose and 2´-deoxyribose 
nucleosides i.e. the eight most common nucleosides constituting RNA and DNA 
(Figure 5). Antiviral properties result from chemical modifications in the 
structure of the nucleobase or sugar moiety or both. The modifications of some 
of the currently approved antiviral nucleosides include addition of functional 
groups or atoms, modification of the furanose ring by substitution of the 
heteroatom or removal of the ring structure, modification or suppression of the 
hydroxyl groups, modification of the nucleobase, and inversion of 
configuration.
23
 In the cell, the nucleoside analogs are phosphorylated by 
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different kinases in multiple steps to become converted to nucleoside 
triphosphates, which are the active forms expressing the antiviral activity. This 
considerably restricts the number of feasible modifications of the nucleosides, as 
several kinases have to recognize the analogs as their substrates. The 
phosphorylation processes are discussed in more detail in the following chapter. 
 
Figure 5 Some modifications of antiviral nucleosides and structures of natural 
ribose and 2´-deoxyribose nucleosides.   
1.2.3 Cell delivery and phosphorylation 
Cell membrane is a fluid structure constituting of phospholipid bilayer and 
proteins functioning as transporters. The nucleoside analogs enter the cell by 
passive diffusion or carrier-mediated transport. The transport is facilitated by 
members of the solute carrier superfamily, in particular by the equilibrative and 
concentrative families of nucleoside transporters, and organic anion 
transporters.
24,25
 Due to the hydrophilicity of the nucleoside analogs, the carrier 
mediated transport has a major role in bringing the compounds inside the cell. 
Adenosine triphosphate (ATP) binding cassette transporters (ABC), in turn, 
efflux phosphorylated nucleoside analogs from the cell. Once inside the cell, the 
analogs can also be eliminated by various catabolic processes.  
To achieve antiviral activity, the nucleoside analogs need to be phosphorylated to 
their triphosphate form. The initial phosphorylation to the nucleoside 
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monophosphate is carried out by a number of nucleoside kinases: 2´-
deoxycytidine kinase, thymidine kinase 1 (TK1), thymidine kinase 2 (TK2) and 
deoxyguanosine kinase. The second phosphorylation step is catalyzed by 
nucleoside monophosphate kinases: thymidylate kinase, uridylate-cytidylate 
kinase, adenylate kinases 1 to 5 and guanylate kinases. The third phosphorylation 
to the nucleoside triphosphate is performed by nucleoside diphosphate kinase. In 
addition, some enzymes, such as phosphoglycerate kinase, pyruvate kinase and 
creatinine kinase, which are involved in reactions producing ATP, can also 
efficiently catalyze triphosphate formation of many nucleotide analogs. 
Nucleoside and nucleotide analogs can also be internalized into the mitochondria, 
where they can be further phosphorylated to the triphosphates. Nucleoside 
triphosphates have been found to inhibit the function of DNA-polymerase , 
which is responsible for mitochondrial DNA replication. This can be the cause of 
mitochondrial toxicity observed with some nucleoside analogs.
26
 Figure 6 
summarizes the discussed cellular processes of nucleoside analogs. 
 
Figure 6 Cell related metabolism of nucleoside analogs. Mechanisms of carrier- 
mediated transport inside the cell: facilitated diffusion (FD), exchange 
(EX), cotransport (CO). (B = Nucleobase). Modified from ref. 
27
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Some DNA viruses, like herpes viruses, encode their own viral kinases, which 
phosphorylate the nucleoside analogs to the monophosphate form in the infected 
cells. Viral thymidine kinase of herpes viruses phosphorylates ACV (Figure 1) to 
its monophosphate 100 times more efficiently than human thymidine kinase. This 
feature is extremely significant relative to antiviral therapy, because it enables 
selectivity of the antiviral nucleosides for virus infected cells.  
1.2.4 Mechanism of action  
The biologically active form of antiviral nucleoside analogs is the nucleoside 5´-
triphosphate. The triphosphates interact with the viral or human polymerases. 
They can act as competitive inhibitors of polymerases or as alternative substrates 
that compete with the natural nucleoside triphosphates in DNA and RNA 
polymerization. Viral polymerases tend to be less substrate selective than the 
enzymes of the host cell and therefore nucleotide analogs become incorporated 
mainly in infected cells. The human replicative DNA polymerases have high 
fidelity which limits the incorporation of nucleotide analogs.   
If incorporated into newly synthesized DNA or RNA, the antiviral nucleotide 
analogs act as chain terminators preventing further chain elongation. Many of the 
analogs lack 3´-hydroxyl function, which is required for the attachment of the 
incoming nucleotide. If the nucleotide analog possess the 3´-hydroxyl group (or a 
hydroxyl group at equivalent position), it can nevertheless act as chain 
terminator, if the hydroxyl group is conformationally constrained or sterically 
hindered. In addition, the incorporation of nucleotide analogs into viral DNA 
may lead to accumulation of mutations in the viral progeny, which weakens the 
virus and its ability to act as pathogen.
 8,28
 
1.3 Prodrug strategies of antiviral nucleotides 
1.3.1  Applying the prodrug concept to antiviral nucleosides 
A prodrug is a precursor of a drug.
29
 It is an inactive agent that is metabolized in 
the body to the active drug by chemical or enzymatic reactions. Prodrug 
approaches are used to improve the physicochemical and, consequently, the 
pharmacological and toxicological properties of a drug. This is achieved by 
temporarily modifying the structure of the active drug with promoieties, 
functional groups that for example, make the molecule more metabolically 
stable, more lipophilic or hydrophilic, or help to target it to a specific cell type.  
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In an ideal case, the prodrug is converted to the parent drug as soon as it reaches 
its target and the remnants of the promoieties are eliminated into non-toxic 
compounds and rapidly excreted from the body.
30
  
In many cases, the first phosphorylation of the antiviral nucleoside to the 
nucleoside 5´-monophosphate is the rate-limiting step in human cells. The first 
kinase in the phosphorylation cascade is the most substrate selective. AZT 
(Figure 1) makes an interesting exception to the rule: it is readily phosphorylated 
to the monophosphate and the bottleneck of the activation is the formation of the 
diphosphate leading to accumulation of AZT monophosphate in the cell.
31
 If 
nucleoside analog is phosphorylated to the diphosphate, it will also most likely 
become phosphorylated to the triphosphate as well, because the enzymes that 
catalyze the final phosphorylation have wide substrate specificity.
32
  
To avoid the problematic first phosphorylation step, the antiviral nucleoside 
should be delivered as its 5´-monophosphate. However, the nucleoside 
monophosphates are poor drug candidates as such. The negative charge on the 
molecule at physiological pH prevents crossing of biological membranes. In 
addition, the monophosphates are susceptible to degradation by phosphatases. In 
order to deliver an antiviral nucleoside monophosphate, a prodrug strategy is 
required (Figure 7). The phosphate group needs to be temporarily masked with 
protecting groups, which make the molecule more lipophilic and allow delivery 
into the cell. Several different types of protecting groups are available.
33
 The 
removal of the protecting groups by chemical or enzymatic processes traps the 
anionic nucleoside monophosphate inside the cell. The released nucleoside 
monophosphate is still a prodrug, as it needs to be further converted to the 
triphosphate form to act as active drug.  
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Figure 7 The prodrug approach of nucleoside monophosphates. 
In addition, the prodrug strategies of nucleoside monophosphates enable the use 
of such nucleoside analogs as drugs, which have not shown antiviral activity due 
to lack of phosphorylation. The repertoire of antiviral nucleosides can, hence, be 
expanded.  The process of activation of inactive nucleoside analogs has been 
termed as ’’kinase by-pass’’.
34
  
To be successful as therapeutics, the prodrugs of antiviral nucleoside 
monophosphates should possess certain properties. The prodrug should be 
soluble in water, but also neutral and lipophilic enough to allow passive diffusion 
across the cell membrane. The prodrug should have sufficiently long half-life in 
serum to be able to reach the target cell. Once inside the cell, it should be 
converted to the active form with optimal kinetics. The prodrugs of nucleoside 
monophosphates as well as the by-products that are released upon conversion to 
active drug should be non-toxic. The prodrug should be stable enough to 
conditions in the gastrointestinal tract and allow formulation into an orally 




1.3.2 Esterase labile protecting groups 
The broad substrate specificity of esterases makes the esterase labile protecting 
groups an extensively studied prodrug class and a wide variety of these 
protecting groups have been reported in the literature. Figure 8 represents six 
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 groups. The last mentioned protecting 
group is additionally thermally removable and this feature is discussed in more 
detail in chapter 1.3.6.  
 
Figure 8 Structures of esterase labile protecting groups. (Nu = nucleoside). 
The esterase labile protecting groups utilize carboxyesterase initiated hydrolysis 
for the release of nucleotides. Carboxyesterases are enzymes that are expressed at 
high levels in various tissues and they accept a wide variety of substrates.
49
 First, 
the carboxyesterase catalyzes the cleavage of the acyl group. The stability of the 
esterase labile protecting groups can be adjusted by the nature of the acyl group: 
the more bulky the acyl group, the more stable the compound is against the 
degradation by carboxyesterase.
50
 After deacylation, spontaneous elimination of 
the rest of the protecting group follows. The remnants of the esterase labile 
protecting groups are released as various side products depending on the group, 
but many of them are potentially toxic.  The POM group releases formaldehyde 
and pivalate ion. The POC and 2,2-substituted 3-acyloxypropyl groups release 
formaldehyde and carbon dioxide together with isopropyl alcohol or enone, 
respectively. AOB groups release 4-hydroxybenzyl cation, which is further 
oxidized to 4-quinonemethidine or hydrolysed to 4-hydroxybenzyl alcohol. 
SATE and 2,2-disubstituted 4-acylthio-3-oxobutyl groups release a cyclic by-
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product as a result of intramolecular cyclisation. As an example, the degradation 
pathways of bis(SATE) and bis(2,2-substituted 3-acyloxypropyl) nucleotides are 
represented in Schemes 1 and 2, respectively. In case of bis-protected nucleoside 
monophosphates, the second protecting group is expected to be removed 
stepwise in same manner or, alternatively, directly by a phosphodiesterase.   
 
Scheme 1 Carboxyesterase triggered degradation of bis(SATE) nucleoside 
monophosphate. 
 
Scheme 2 Carboxyesterase triggered degradation of bis(2,2-substituted 3-
acyloxypropyl) nucleoside monophosphate. 
The POM and SATE groups
51,52,53
 as well as the 2,2-substituted 3-acyloxypropyl 
groups
54,55
  have also been applied to the protection of phosphorothioate bonds of 
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oligonucleotides. These studies demonstrate well that when the molecule 
contains more than one protecting group, the protections are removed at different 
rates by the enzyme. The first POM protection of a dodecathymidine bearing 
three POM protections was removed very rapidly by PLE (8 U mL
-1
 ) with half-
life of less than 2 minutes, while the remaining POM protections were removed 
much more slowly, the half-life for the fully deprotected oligomer being 2.4 
hours.
53
 In case of octathymidine bearing two 2,2-substituted 3-acyloxypropyl 
groups, the removal of the second protecting group was markedly retarded as 
well and additionally concurrent phosphorothioate backbone degradation took 
place.
55
 Kinetic studies with bis-protected monophosphates bearing 2,2-
substituted 3-acyloxypropyl groups also support the finding: enzymatic 
deacetylation of the negative phosphodiester is 10
3
 times slower than 
deacetylation of the neutral phosphotriester.
47
 Carboxyesterases prefer neutral 
substrates and the negative charge, which is formed after the removal of the first 
protecting group, disturbs the functioning of the catalytic site of the enzyme 




The mixed SATE phosphoesters combine two different deprotection 
mechanisms. The nucleotide is protected with one SATE group and either an 
aryl, an amino or a glucosyl residue (Figure 9).
56
  The SATE protection is first 
removed by carboxyesterase. The aryl derivative is then assumed to be removed 
by nucleotide phosphodiesterases, the amino residue by phosphodiesterase or 
phosphoramidase activation and the glucosyl moiety by glucosidases.  
 
Figure 9 Mixed SATE prodrugs. 
The esterase labile SATE, POM and POC residues have also been used to protect 
3´,5´-cyclic monophosphates of base-modified 2´-C-methylribonucleosides.
57
 
The 3´,5´-cyclic prodrugs showed enhanced potency in HCV inhibition studies 
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and improved antiviral activity against bovine viral diarrhea virus, a replicon 
model for HCV, compared to sheer nucleosides. The compounds were stable in 
simulated intestinal and gastric fluids as well as in human plasma, indicating that 
they are capable of reaching the hepatocytes intact. No significant cytotoxicity 
was observed. The esterase labile protecting groups suit well for the protection of 
3´,5´-cyclic monophosphates, because only one protecting group is needed and 
thus the problem of slow removal of the subsequent esterase labile protections 
can be avoided. After removal of the esterase labile protecting group, the 
remaining 3´,5´-cyclic phosphate is hydrolyzed to 5´-monophosphate by 
phosphodiesterases. 
Another cyclic approach, which requires only one esterase catalyzed activation 
step, utilizes 1-pivaloyloxypropan-1,3-diyl group as a cyclic phosphate 
protection of nucleoside monophosphate.
 58
 The removal of the pivaloyl group by 
carboxyesterase triggers the degradation of the protecting group (Scheme 3). The 
ring structure opens up to form an aldehyde. Spontaneous elimination of acrolein 
follows and the nucleoside monophosphate is released. The by-product acrolein 
is highly reactive. It can cause toxicity problems at high doses and has been 
associated with hemorrhagic cystitis. However, the toxicity can be controlled by 
concurrent administration of sodium 2-mercaptoethanesulfonate, which reacts 
with acrolein to produce non-toxic thioether. The 5´-[4-(pivaloyloxy)-1,3,2-
dioxaphos-phorinan-2-yl]-2´-deoxy-5-fluorouridine was converted to the 
monophosphate with half-life of 5.9 hours, when exposed to hog liver 
carboxylate esterase (3 U mL
-1
). When incubated with mouse plasma in 0.05 M 
phosphate buffer, the half-life for degradation was 30 minutes. 
 
Scheme 3 Removal of 1-pivaloyloxypropan-1,3-diyl protecting group. 
Some of the bis(AOB) esters of AZT monophosphates show increased 
cytotoxicity due to the side products released on deprotection. Attempts have 
been made to reduce the toxicity by using the AOB group to protect a 5´,5´-dimer 
of AZT, which releases only one potentially toxic 4-hydroxybenzyl cation
 
 per 
one nucleotide and one nucleoside.
59
 In addition, the AOB esters have been used 
to deliver nucleoside diphosphates of d4T and AZT.
60,61 
In the so called DiPPro-
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approach the -phosphate moiety is protected by two AOB groups (Figure 10). 
The -phosphate is left unmasked, because the negative charge prevents the 
rapid cleavage of the anhydride bond by nucleophiles. However, acyloxybenzyl 
esters with short or branched acyl groups showed no antiviral activity in 
thymidine kinase deficient CEM cells (CEM/TK
-
). The remaining polarity on the 
molecule possibly prevents effective cellular uptake. By increasing the 
lipophilicity of the molecule with longer chains of the acyl moieties, this obstacle 
was avoided and, for instance, 4-decanoyloxybenzyl ester of d4T diphosphate 
had 10-fold higher antiviral activity in HIV-1 infected wild-type CEM cells and 
1570-fold higher antiviral activity in the CEM/TK
-
 cell assay relative to d4T.  
However, when the DiPPro-strategy was applied to uridine nucleoside analogues 
2´,3´-didehydro-2´,3´-dideoxyuridine and 2´,3´-didehydrouridine, the compounds 
showed low or no antiviral activity in HIV infected cells.
62 
The uridine analogs 
were released as their nucleoside diphosphates, but studies with nucleoside 
diphosphate kinase showed that the released diphosphates are poor substrates for 
the enzyme and thus the triphosphates are not formed. This might explain the 
poor antiviral activity of the uridine analogs.  
Recently, the 4-acyloxybenzyl ester strategy has also been applied to 
triphosphates in the TriPPPro-approach, where the -phosphate of the d4T 
triphosphate is protected with two identical or different 4-acyloxybenzyl groups 
(Figure 10).
63
 The underlying idea is the same as in the DiPPro-approach, but 
more detailed information on the TriPPPro-approach is not yet available.  
 
Figure 10 The 4-acyloxybenzyl esters studied in the DiPPro- and TriPPPro-
approaches. 
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1.3.3 Reductase labile protecting groups 
The removal of S-[(2-hydroxyethyl]sulfidyl]-2-thioethyl (SDTE) group is 
comparable to the removal of SATE groups, but the activating enzyme is 
different. The disulfide bond is first cleaved by reductase and then, an episulfide 
is spontaneously eliminated (Scheme 4). The limitations of this protecting group 
include the potential toxicity as a consequence of episulfide release and high 





Scheme 4 Reductase triggered degradation of bis(SDTE) nucleoside 
monophosphate. 
Nitrofuranylmethyl protection has been applied to protect phosphoramidates of 
anticancer nucleoside 5-fluoro-2´-deoxyuridine.
65
 The removal of the protecting 
groups is triggered by enzymatic reduction of the nitrofuranylmethyl group, 
which leads to release of iminium and phosphoramidate ions (Scheme 5). The 
haloalkylamine group then undergoes spontaneous intramolecular cyclization and 
attack by water releases the nucleoside monophosphate.  
 
Scheme 5 Proposed mechanism for the deprotection of nitrofuranylmethyl 
nucleoside phosphoramidates.  
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1.3.4 Oxidatively removable protecting groups 
Cyclic 1-aryl-1,3-propanyl esters (HepDirect) of nucleoside monophosphates are 
targeted to treat liver diseases.
66
 The removal of HepDirect protecting groups 
starts in the hepatocytes by oxidation catalyzed by cytochrome P450 (CYP) 
enzymes. The oxidation generates a cyclic hemiketal, which undergoes 
spontaneous ring opening, and an aryl vinyl ketone is cleaved by -elimination 
(Scheme 6). The released aryl vinyl ketone is an alkylating agent and hence, 
potentially toxic, but cells expressing CYP enzymes also produce high levels of 
glutathione, which is expected to capture the toxic side product as glutathione 
conjugate.  
 
Scheme 6 Degradation of HepDirect prodrugs. 
The HepDirect concept has been evaluated in human clinical trials for the 
delivery of adefovir to treat hepatitis B infection.
67
  The prodrug was safe and 
well tolerated with only mild adverse effects. The HepDirect concept has also 
been applied to cytarabine [1-(β-D-arabinofuranosyl)cytosine, araC] 
monophosphate
68
 to treat hepatocellular carcinoma. In mice, the prodrug was 
shown to generate high levels of araC triphosphate in the liver. In addition, the 






3´,5´-Cyclic prodrugs with isopropyl as phosphate protection have been shown to 
be degraded by CYP enzymes and by subsequent ring opening by 
phosphodiesterases.
71
 Adenosine deaminase-like protein 1 (ADAL1) catalyzes 
the removal of the O
6
-ethyl group on the nucleobase and releases the nucleotide, 
a potential inhibitor of HCV replication (Scheme 7). In addition, other alkyl 
groups were studied as phosphate protections of 3´,5´-cyclic nucleoside 
monophosphates and cycloalkyl groups were shown to be significantly more 
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Scheme 7 Deprotection of isopropyl protected 3´,5´-cyclic monophosphate. 
Nucleotide lipid esters are also oxidized in the hepatocytes.
73
 The long chain 
alkyl group that is used to mask the monophosphate is first oxidized by 
cytochrome P450 species to the acid form, and then broken down in 
peroxisomes, two carbons at a time, by enzymatic -oxidation (Scheme 8).
74
 
Lipid esters of nucleoside monophosphates are readily delivered inside the cell 
and they do not liberate any toxic side products.  
 
Scheme 8 Degradation of lipid ester nucleotide by enzymatic -oxidation. 
Lipids have been conjugated especially to anticancer nucleosides araC and 
gemcitabine (2´,2´-difluorodeoxycytidine),
8
 but in addition, lipid esters of AZT 
monophosphate and tenofovir have been evaluated in clinical studies against 
HIV. A thioether lipid protecting group has been used to improve organ and cell 
selectivity of AZT monophosphate.
75
 The prodrug is readily cleaved in 
mononuclear cells, but poorly in red blood cells and stem cells. This should 
reduce the hematologic toxicity, which is the main dose limiting adverse effect of 
AZT. Unlike tenofovir disoproxil fumarate, which is rapidly converted to 
tenofovir dianion by plasma esterases, hexadecyloxypropyl ester of tenofovir 
remains intact in plasma enabling more effective uptake by target cells.
76
  The 
50% lower effective concentration (EC50) of the lipid ester of tenofovir may 
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reduce renal toxicity, which has been found to appear at elevated concentrations 
of tenofovir.  
1.3.5 Phosphoramidase labile protecting groups 
Phosphoramidates constitute an extensively studied class of protecting groups. In 
the first reported structure, an aryl group and an L-alanine methyl ester were used 
to mask the phosphate.
77
 The removal of the protecting groups is initiated by 
esterase-mediated hydrolysis of the methyl ester (Scheme 9). This leads to 
intramolecular cyclization and release of a phenol. The five membered 
intermediate is rapidly hydrolyzed to phosphoramidic acid. The last step in the 
deprotection cascade of the nucleoside monophosphate may be catalyzed by a 




Scheme 9 Degradation of aryl phosphoramidate prodrugs. 
An amino acid is required for the antiviral activity. Studies have shown that 
simple amine substitution leads to a complete loss of antiviral activity.
80
 
Moreover, L-amino acids are preferred over D-amino acids, and especially L-
alanine shows significant antiviral activity.
81
 However, a natural amino acid is 
not necessarily required for the antiviral activity. An aryl phosphoramidate of 
d4T derived from the methyl ester of ,-dimethylglycine is only 3 times less 
potent against HIV-infected cells than the corresponding derivative of L-alanine 
methyl ester.
82
 In addition, it has been demonstrated that the amino acid derived 
phosphoramidates can act as alternative substrates for HIV-1 reverse 
transcriptase and may be incorporated into the DNA.
83
 Hence, the antiviral effect 
of the amino acid phosphoramidate does not necessarily require the conversion of 
the 5´-phosphoramidic acid to the 5´-phosphate. The alaninyl d4T-
monophosphate has been observed to accumulate and it has been suggested that 
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this intermediate could serve as intra- and/or extracellular depot for the 
nucleoside monophosphate.
84
 The amino acid ester prodrugs of nucleoside 
analogues have also been shown to be substrates for the peptide intestinal 
transporter (PepT1).
85
 PepT1 is stereoselective preferring L-amino acids.  
With aryl phosphoramidates, the concerns that need to be taken into account are 
the toxicity of the phenol byproduct at modest concentrations, and the 
stereoisomerism that results from the attachment of two different groups to 
phosphorus atom. By attaching two identical amino acid groups to the 
phosphorus atom, both the toxicity and stereoisomer issues are avoided. Various 
diamide prodrugs of AZT monophosphate bearing two identical amino acids 
have been synthesized and tested against HIV-1 infected cells in vitro (Figure 
11).
86
 It was demonstrated that, in most cases, non-polar amino acid side-chains 
show greatest antiviral activity. In addition, the diamide strategy has been applied 
to a novel acyclic nucleoside phosphonate (GS-9219, Figure 11) and the 
compound has been evaluated in human clinical trials for the treatment of 
leukemia,
87




Figure 11 Structures of phosphorodiamidate and 3´,5´-cyclic phosphoramidate 
prodrugs.  
Also with cyclic phosphoramidates the use of phenol protection is circumvented 
as only one protecting groups is needed to mask the 3´,5´-cyclic structure, but the 
formation of two diastereomers due to the 3´,5´-cyclic structure still has to be 
taken into account. A series of 3´,5´-cyclic phosphoramidates of 2´-C-
methylcytidine, protected with 15 different amino acid esters, have been studied 
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as inhibitors of HCV (Figure 11).
89
 The antiviral activity and conversion to 
nucleoside triphosphate (NTP) was examined in human hepatocytes. The 3´,5´-
cyclic phosphoramidates were efficiently converted to the active triphosphate 
species. The levels of NTP formed depend on the structure of amino ester: the 
more lipophilic esters yield higher levels of NTP and also introduction of oxygen 
into the ester side chain raises NTP levels whereas branched esters did not have 
large effect on the NTP formation. There seem to be no preference in terms of 
diastereomers, when it comes to levels of NTP formation.  
1.3.6 Chemically removable protecting groups 
Cyclosaligenyl (cycloSal) phosphotriester approach is one of the few prodrug 
strategies that do not require enzymatic activity in any step of the release of the 
monophosphate. The concept has been widely studied and applied to several 
nucleoside analogs.
90
 The removal of cyclosaligenyl protecting group proceeds 
stepwise by selective chemical hydrolysis (Scheme 10).
91,92,93
  The selectivity is 
based on the different stability of the phenyl- and benzyl phosphate ester. The 
phenyl ester bond of the cycloSal monophosphate is the most labile of the three 
ester bonds, as the negative charge formed upon the bond breaking is delocalized 
into the benzene ring. After selective hydrolysis of the phenyl ester bond, the 
formed 2-hydroxybenzylphosphodiester then breaks down rapidly, releasing the 
nucleoside monophosphate and 2-hydroxybenzyl alcohol. The initial activation 
step can be controlled by the nature of the substituents in position 5 of the 
aromatic ring. Electron withdrawing substituents (NO2, Cl) accelerate the 
cleavage of the phenyl ester bond, while electron donating substituents (Me) 
stabilize the same bond. In addition, the degradation of the cycloSal protecting 
group is pH dependent, the hydrolysis being slower under acidic conditions. In 
the cycloSal approach only one protecting group per nucleotide is needed.  
 
Scheme 10 Removal of cycloSal protecting group.  
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The salicyl alcohols that are released as by-products have not shown 
cytotoxicity,
94
 but CycloSal phosphate triesters have been reported to inhibit 
butyrylcholinesterase in human and mouse serum.
95
 The inhibitory effect is 
highly dependent on the nature of the nucleoside and the substituent on the 
cycloSal moiety.  Bulky alkyl substituents in position 3 of the aromatic ring 
reduce the inhibition activity and the effect is even stronger with substituents at 
both m-positions, 3 and 5. The stereochemistry around the phosphorus atom also 
has a marked impact on the inhibitory effect: the SP-diastereomers inhibit the 
enzyme while the RP-diastereomers do not. The most promising cycloSal 
masking group thus far is the 3,5-di-tert-butyl-6-fluoro-cycloSal group.
96
 In 
antiviral tests with HIV-1- and HIV-2-infected wild-type CEM cells the 3,5-di-
tert-butyl-6-fluoro-cycloSal protected monophosphate of d4T showed enhanced 
antiviral activity compared to d4T.  
There are several modifications of the cycloSal protecting group (Figure 12). The 
bis(cycloSal) approach delivers two nucleoside monophosphates per one 
protecting group.
97
 The increased steric hindrance due to the size of the molecule 
reduces the butyrylcholinesterase inhibitor activity. CycloSal protecting groups 
have also been modified by introducing enzymatically activated substituents to 
the aromatic ring. Due to the chemically triggered removal mechanism and 
lipophilic character of the initial cycloSal phosphotriesters, the compounds form 
concentration equilibrium through the cell membrane. The enzymatically 
activated cycloSal compounds, however, allow trapping of the molecule inside 
the cell, because the intracellular enzymatic removal of the substituent at the 
aromatic ring releases a more polar cycloSal derivative. After enzymatic 
activation, the rest of the cycloSal protection is hydrolyzed chemically. The 
substituents of these modified cycloSal derivatives include esterase labile 
groups
98,99,100,101,102
 and amino acid esters
103
 (Figure 12).   
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Figure 12 Structures of cycloSal protecting group modifications.  
Another class of protecting groups that do not require enzymatic activation 





 and several ω-(alkylthio)alkyl
106
 
groups. These protecting groups are expected to be removed by intramolecular 
cyclization reaction at 37 C in aqueous environment near neutral pH. The 
protecting groups have been studied as thermolabile thiophosphate protecting 
groups of oligonucleotides. The removal of the (N-formyl-N-methyl)-2-
aminoethyl group is depicted in Scheme 11. The half-lives for the thermolytic 
deprotection have been studied with thymidine derived dinucleoside 
phosphorothioate triesters.
106
 The half-lives for the conversions of Tps(OR)T to 
TpsT in phosphate buffered saline at 37 C vary from 6.5 h to 38 h. 
 
Scheme 11 Removal of (N-formyl-N-methyl)-2-aminoethyl protection by 
intramolecular cyclization. 
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2,2-disubstituted 4-acylthio-3-oxobutyl groups have been studied as 
phosphodiester bond protections.
48
 These groups are esterase labile protecting 
groups that are additionally thermally removable. The underlying idea is that the 
protecting groups will be removed by thermolytic departure in case the 
enzymatic reaction markedly slows down, as can be the case when more than one 
esterase labile protection is applied to protect one molecule. The non-enzymatic 
removal of these groups is initiated by hydration of keto group, which enables 
the migration of acyl group from the sulfur atom (Scheme 12). The exposed 
mercapto group can then attack C1 leading to release of the phosphodiesters. The 
protecting group departs as 4,4-disubstituted 3-acyloxy-4,5-dihydrothiophene. 
 
Scheme 12 Removal of 2,2-disubstituted 4-acylthio-3-oxobutyl groups by 
intramolecular cyclization. 
2-[(Acetyloxy)methyl]-4-(acetylsulfanyl)-2-(ethoxycarbonyl)-3-oxobutyl group 
is also removable both enzymatically as well as thermally (Scheme 13).
107
 
Instead of intramolecular cyclization reaction, the non-enzymatic removal occurs 
by retro-aldol condensation releasing enone as by-product. 
38 Introduction 
 
Scheme 13 Removal of 2-[(acetyloxy)methyl]-4-(acetylsulfanyl)-2-(ethoxy-
carbonyl)-3-oxobutyl group by retro-aldol condensation. 
Three different bis-ketol protections have been introduced to 5´-monophosphates 
of 3´-deoxythymidine (ddT) and d4T as chemically removable phosphate 
protections.
108
 The antiviral activity of the compounds against HIV has been 
studied. The bis-ketol protected phosphate triesters of ddT showed enhanced 
antiviral activity and the EC50 value was at least 10-fold lower when compared to 
the parent ddT. On the other hand, the bis-ketol protections did not improve the 
EC50 value of d4T significantly. The suggested pathway for the removal of bis-
ketol protections is represented in Scheme 14.  
 
Scheme 14 Proposed removal mechanism of bis-ketol protections. 
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1.3.7 Prodrug strategies of nucleotides in clinical trials 
Enzymatically removable protecting groups constitute a versatile and well-
established class of phosphate protections for the delivery of nucleotides into the 
cell. Two prodrugs based on esterase labile protecting groups have been 
approved for human use. Adefovir dipivoxil (Figure 2) is a bis(POM) protected 
monophosphate of adefovir, which is an acyclic adenosine phosphonate 
derivative and an anti-HBV nucleoside.  Tenofovir disoproxil fumarate (Figure 
2) is a bis(POC) protected prodrug of tenofovir, which is likewise an acyclic 
adenosine phosphonate derivative and has antiviral activity against HIV.  
Another widely studied prodrug class is phosphoramidates. As Table 1 indicates, 
majority of the nucleotide prodrug candidates currently in clinical trials are 
phosphoramidate derivatives.
8
 The potential of phosphoramidate prodrugs was 
recently proofed, when sofosbuvir was accepted for medical use against HCV 
infection in humans. Sofosbuvir is a prodrug of 2´--fluoro-2´--methyluridine 
monophosphate, where the phosphate moiety is protected with a phenyl group 
and an isopropyl ester of L-alanine (Figure 2). There have been drawbacks with 
phosphoramidate prodrugs as well. IDX-184 and IDX-19368 are 5´-
phosphoramidates of 2´-C-methylguanosine that have been shown to be pan-
genotypic against HCV.
109
 In addition, the compounds show no inhibition of 
human polymerases and are readily converted into triphosphates in animal liver. 
Nevertheless, studies with practically all guanosine analogues have been 
discontinued after one volunteer died on cardiac failure and 40% of the 
volunteers had some kind of cardiac dysfunction in phase II studies of a 
guanosine derived phosphoramidate prodrug (BMS-986094).
110
  
Other potential future prodrug classes that have proceeded to preclinical or 
clinical development are based on cycloSal, HepDirect, SATE and lipid ester 
protections. The advantageous feature of cycloSal and HepDirect prodrugs is that 
only one by-product molecule is released per one nucleoside monophosphate, 
due to the cyclic structure of the protecting groups. In most of the prodrug 
approaches two equivalents of potentially toxic by-products are released per one 
active molecule. Salicylic alcohols that are released as by-products of cycloSal 
protections have not shown cytotoxicity. Similarly, the lipid ester prodrugs do 
not liberate toxic by-products. The aryl vinyl ketone that is released from the 
HepDirect prodrugs, on the other hand, is toxic. Since the degradation of 
HepDirect compounds occurs in the liver, where high levels of glutathione is 
produced, this may not be a problem. Formaldehyde is a common by-product of 
many of the esterase labile protecting groups and has been named as a known 
human carcinogen.
111
 However, formaldehyde is an essential metabolite of the 
body and we are also exposed to it from the environment and our food. Adefovir 
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dipivoxil and tenofovir disoproxil fumarate generate 1.2 mg and 28.1 mg of 
formaldehyde per dose of prodrug (10 mg and 300 mg) during bioconversion, 
respectively.  It is estimated that the body uses 31 to 59 g of formaldehyde per 
day, so the additional formaldehyde from the prodrugs should be easily handled 
by the body.
112
 The removal of SATE group releases an episulfide, which is an 
alkylating agent, but nevertheless at least two nucleotide prodrugs utilizing 
SATE protecting groups are studied in preclinical trials for cancer treatment. 
Table 1 Approved nucleotide prodrugs and prodrug candidates in preclinical or 
clinical development, their target, year of approval or status of 
development and the applied prodrug strategy. Modified from ref.
8
 
Name Target Status Prodrug strategy Ref., NB  
Sofosbuvir  HCV 2013 Phosphoramidate 
11,113
 





HIV, HBV 2001, 2008 POC 
10,116 
UA911 cancer preclinical SATE 
117
 
Mixed SATE-araCMP cancer preclinical SATE 
118
 
CycloSal-CdAMP cancer preclinical CycloSal 
119
 
Phosphoramidate-araC cancer preclinical Phosphoramidate 
120
 
NUC-1031 cancer Phase I Phosphoramidate 
121
 




NB1011 cancer Phase I/II Phosphoramidate 
123 
GS-9131 HIV Phase II Phosphoramidate 
124,125 
GS-7340 HIV, HBV Phase I/II Phosphonoamidate 
126,127
 
Stampidine HIV Phase I Phosphoramidate 
128
 
CMX157 HIV Phase I Lipid ester 
76 
Pradefovir HBV Phase II HepDirect 
129
 
PSI-353661 HCV Phase I Phosphoramidate 
130 
IDX-19368 HCV Phase I Phosphoramidate 
109
† 
IDX-184 HCV Phase II SATE+Phosphora. 
131
† 
INX-08189 HCV Phase II Phosphoramidate 
132
† 
† Symbol refers to discontinuation of the studies. 
 
In prodrug strategies, where diastereomers are formed, the different physical 
properties of single diastereomers need to be evaluated as well. Diastereomers 
are formed in synthesis of the mixed prodrug strategies, where two different 
protecting groups are used to mask the phosphate, and also in the cyclic 
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protecting group strategies. Sofosbuvir, for instance, is used as single 
diastereomer. 
As for any drug, also in case of prodrugs of antiviral nucleotides, the issue of 
toxicity is not straightforward. How efficiently the compound reaches its target 
and acts as a drug is important in determining the risks in addition to the toxicity 
of the by-products. The efficiency determines on its behalf the size of the dose 
and hence, the amount of released toxic compound as well. In addition, how 
serious a disease is and the existence or lack of other treatment options counts in 
the assessment of the overall risks of a drug. If benefits are bigger than risks, the 
compound has potential for drug use. The toxicity issue becomes emphasized 
especially in the treatment of long term or chronic viral infections, such as HIV, 
where drugs need to be taken throughout lifetime.  
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2 AIMS OF THE THESIS 
Antiviral nucleosides have proved their potential in the treatment of several viral 
infections. The bottle neck of the therapy utilizing antiviral nucleosides often is 
inefficient phosphorylation to the nucleoside monophosphate, which leads to low 
antiviral activity. The first phosphorylation step can be bypassed by delivering 
the antiviral nucleoside directly as its protected monophosphate derivative i.e. 
applying a prodrug strategy. Many prodrug strategies are based on enzymatically 
cleavable protections, esterase labile protecting groups in particular. However, 
several studies have demonstrated that, in case of carboxyesterase labile 
protecting groups, the rate of the removal of the second and subsequent 
protecting groups is significantly retarded. This is due to the negatively charged 
phosphodiester intermediate which is formed after the first protecting group is 
removed. The negative charge disturbs the active site of the enzyme.    
This thesis is aimed at studying carboxyesterase labile protecting group strategies 
where the issue of retardation could be avoided.  Potential prodrug candidates of 
antiviral nucleosides have been synthesized, including: 
 Nucleoside phosphoramidates bearing a carboxyesterase labile protecting 
group and an L-alanine methyl ester.  
 5´,5´-dinucleoside monophosphates bearing a carboxyesterase labile 
protecting group. 
 3´,5´-cyclic nucleosides bearing a carboxyesterase labile protecting group. 
In the synthesized compounds, the second protecting group is cleaved by some 
other mechanism than carboxyesterase triggered activation or the structure of the 
prodrug requires only one protecting group. Kinetic studies on the chemical and 
enzymatic stability of some of the synthesized compounds were carried out. 
In addition, carboxyesterase labile protecting group which is additionally 
thermally removable was used as phosphate protecting group of short oligomeric 
phosphodiesters. The idea of this protecting group, which is removable by two 
mechanisms, is that in case the enzymatic removal becomes slow, the protecting 
group will undergo thermolytic departure instead. Kinetic studies with the 
synthesized thymidine derived model compounds were carried out to find out 
how the protecting group is removed from molecules with more than one such 
protection. 
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3 RESULTS  
3.1 Synthesis 
3.1.1 2,2-Bissubstituted 3-acyloxypropyl protected 5´-phosphoramidates (I) 
Antiviral nucleosides ribavirin and 2´-O-methylcytidine were converted to L-
alanine methyl ester derived 5´-phosphoramidates. 3-Acetyloxy-2,2-
bis(ethoxycarbonyl)propyl and 3-acetyloxymethoxy-2,2-bis(ethoxycarbonyl)-
propyl groups were used as esterase labile protecting groups.
47
 To allow 
comparison, the extensively studied O-phenyl phosphoramidates were also 
synthesized. 
The nucleosides were first appropriately protected. Levulinoyl (Lev) groups were 
used to protect the 2´- and 3´-hydroxyl functions of ribavirin and 3´-hydroxyl 
group of 2´-C-methylcytidine. To achieve this, 4-methoxytrityl (MMTr) and tert-
butyldimethylsilyl (TBDMS) groups were first introduced to 5´-O of ribavirin 
and 2´-O-methylcytidine, respectively. The 4-amino function of 2´-O-
methylcytidine was 4-methoxytritylated. The amino function of the ribavirin base 
moiety is not reactive and could be left unprotected. Levulinic anhydride was 
generated in situ from levulinic acid with N,N'-dicyclohexylcarbodiimide (DCC) 
using 4-dimethylaminopyridine (DMAP) as catalyst. Finally, the 5´-O-
protections were removed. The synthetic details to obtain protected nucleosides 1 
and 4 are given in Schemes 3 and 4 of paper I.  
The 5´-O-phenylphosphoramidates of ribavirin (3) and 2´-O-methylcytidine (6) 
were obtained as a mixture of RP- and SP-diastereomers (Schemes 15 and 16) by 
following a previously published method.
133
 The protected nucleosides 1 and 4 
were first reacted with diphenylphosphite in pyridine under nitrogen atmosphere. 
The formed 5´-H-phosphonate phenyl esters were then oxidatively aminated with 
L-alanine methyl ester to obtain 2 and 5 in fairly good yields (67% and 70%, 
respectively). The levulinoyl protecting groups were removed with hydrazine 
hydrate in a mixture of acetic acid (AcOH) and pyridine. The MMTr-protection 
was removed in 80% aqueous AcOH.  
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Scheme 15 Synthesis of compound 3: i) diphenylphosphite, Py, 20 min, ii) L-alanine 
methyl ester in MeCN/Py (6:1), CCl4, TEA, 70 min, iii) 0.5 M N2H4·H2O 
in AcOH/Py (4:1), 1 h. 
 
Scheme 16 Synthesis of compound 6: i) diphenylphosphite, Py, 30 min, ii) L-alanine 
methyl ester in MeCN/Py (6:1), CCl4, TEA, 70 min, iii) 1. 0.5 M 
N2H4·H2O in AcOH/Py (4:1), 5 h, iv) 80% aq. AcOH, 55 ºC for 2 h, 65 
ºC for 4.5 h. 
The 3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl and 3-acetyloxymethoxy-2,2-
bis(ethoxycarbonyl)propyl protected phosphoramidates of  ribavirin (9a, 9b) and 
the 3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl protected phosphoramidate of 2´-
O-methylcytidine (11) were obtained as a mixture of RP- and SP-diastereomers as 
depicted in Schemes 17 and 18, respectively. The syntheses of the starting 
materials, diethyl 2-acetyloxymethyl-2-hydroxymethylmalonate (7a) and diethyl 
2-acetyloxymethoxymethyl-2-hydroxymethylmalonate (7b), have been 
previously described.
47
 7a or 7b was first reacted with diphenylphosphite under 
nitrogen. The phenol was then displaced from the mixed alkyl phenyl H-
phosphonate diester with protected nucleoside 1 or 4. Oxidative amination with 
L-alanine methyl ester gave 8a and 8b in moderate yields (44% and 37%, 
respectively). 10 was obtained in low yield (24%). The levulinoyl and MMTr-
protections were removed as described above for 2 and 5.  
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Scheme 17 Synthesis of compounds 9a and 9b: i) diphenylphosphite, Py, 30 min, ii) 
compound 1 in Py, 2 h iii) L-alanine methyl ester in Py, MeCN, CCl4, 
TEA, 45 to 75 min, iv) 0.5 M N2H4·H2O in AcOH/Py (4:1), 0.5 to 4 
hours. 
 
Scheme 18 Synthesis of compound 11: i) diphenylphosphite, Py, 40 min, ii) 
compound 4 in Py, 2.5 h iii) L-alanine methyl ester in Py, MeCN, CCl4, 
TEA, 60 min, iv) 0.5 M N2H4·H2O in AcOH/Py (4:1), 75 min, v) 80% 
aq. AcOH, overnight. 
3.1.2 5´,5´-phosphodiesters and 3-acetyloxymethoxy-2,2-bis(ethoxycarbo-
nyl)propyl and pivaloyloxymethyl protected 5´,5´-phosphodiesters (II) 
A set of 5´5-phosphodiesters of 2´-C-methylnucleosides was synthesized. One of 
them, viz.  bis(2´-C-methyladenosine) 5´5-phosphodiester was additionally 
protected with an esterase labile 3-acetyloxymethoxy-2,2-
bis(ethoxycarbonyl)propyl or a pivaloyloxymethyl group. To allow 5´-
phosphitylation, 2´-C-methyladenosine, 2´-C-methylguanosine and 2´-C-
methyluridine were appropriately protected. With the purine nucleosides, the 5´-
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hydroxyl group was silylated and the base moiety amino groups 
monomethoxytritylated, as described above for 4. With 2´-C-methyl uridine, the 
5´-O was monomethoxytritylated.  The 2´- and 3´-hydroxyl functions of 2´-C-
methyladenosine and 2´-C-methyluridine were then protected with levulinoyl and 
benzoyl (Bz) groups, respectively. The 3´-hydroxyl function of 2´-C-
methylguanosine was protected either with levulinoyl or benzoyl group, while 
the 2´-O was left unprotected.  The 5´-O-protections were finally removed. The 
synthetic details are given in Schemes 1-3 of paper II. 
The synthesis of 2´-C-methyladenosine derived di- and triesters are outlined in 
schemes 19 and 20. 2´,3´-Di-O-levulinoyl-N
6
-(4-methoxytrityl)-2´-C-
methyladenosine (12) was first phosphitylated with half equivalent of 1,1-
dichloro-N,N-diisopropylphosphinamine in dry dichloromethane (DCM) and 
triethylamine (TEA) under nitrogen. To obtain bis[(2´,3´-di-O-levulinoyl-N
6
-(4-
methoxytrityl)-2´-C-methyladenosin-5´-yl] phosphate (13), the diisopropylamino 
group of the dinucleoside phosphoramidate was displaced with H2O using 1H-
tetrazole activation in MeCN and subsequent oxidation with iodine under 
aqueous conditions. The pivaloyloxymethyl group was introduced by reacting 13 
with chloromethyl pivalate in N-methylpyrrolidone.  The pivaloyloxymethyl 
bis(2´-C-methyladenosin-5´-yl) phosphate (15) was obtained in low yield (15%). 
 
Scheme 19 Synthesis of compound 15: i) iPr2NPCl2, TEA, DCM, 2 hours, ii) H2O, 
1H-tetrazole, MeCN, 75 min,  iii) 0.15 M I2 in a mixture of THF, H2O 
and 2,6-lutidine (4:2:1), 2.5 hours, iv) PivOCH2Cl, NMP, TEA, 60 °C, 4 
days, v) H2NNH3OAc, DCM, MeOH, 18 hours, vi) 80% aq. AcOH, 24 
hours. 
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To obtain 3-acetyloxymethoxy-2,2-bis(ethoxycarbonyl)propyl protected 5´,5´-
phosphodiester 16, the diisopropylamino group of the dinucleoside 
phosphoramidite was displaced with diethyl 2-acetyloxymethoxymethyl-2-
hydroxymethylmalonate (7b) (Scheme 20). The product was then oxidized as 
above. The levulinoyl protections were removed with hydrazinium acetate in 
MeOH and the MMTr-protection in 80% aqueous AcOH. The 3-
acetyloxymethoxy-2,2-bis(ethoxycarbonyl)propyl bis(2´-C-methyladenosiny-5´-
yl) phosphate (17) was obtained in moderate yield (57%). 
 
Scheme 20 Synthesis of compound 17: i) iPr2NPCl2, TEA, DCM, 2 hours, ii) 
compound 7b, 1H-tetrazole, MeCN, 60 min,  iii) 0.15 M I2 in a mixture 
of THF, H2O and 2,6-lutidine (4:2:1), 2.5 hours, iv) H2NNH3OAc, DCM, 
MeOH, 23 hours, v) 80% aq. AcOH, 20 hours. 
The 5´,5´-phosphodiesters of 2´-C-methylguanosine and 2´-C-methyluridine 
were synthesized as depicted in Schemes 21 and 22. A protected nucleoside was 
first phosphitylated with 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite, 
coupled with one equivalent of protected nucleoside and finally oxidized as 
previously. The levulinoyl and 2-cyanoethyl groups were removed with 
methanolic ammonia and the MMTr-protection with 80% aqueous AcOH. The 
ammonium ion was exchanged to sodium ion with strong cation exchange resin.  
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Scheme 21 Synthesis of compounds 22 and 23:  i) NC(CH2)2O(iPr2N)PCl, TEA, 
DCM, 60 min, ii) compound 18 or 19, 1H-tetrazole, MeCN, 1.5 to 2 
hours,  iii) 0.15 M I2 in a mixture of THF, H2O and 2,6-lutidine (4:2:1), 
2.5 hours, iv) NH3, MeOH, 20 hours, v) 80% aq. AcOH, 3 days vi) 
Dowex 50WX8 Na
+
 form, H2O. 
 
Scheme 22 Synthesis of compound 26: i) NC(CH2)2O(iPr2N)PCl, TEA, DCM, 60 
minutes, ii) compound 19, 1H-tetrazole, MeCN, 2 hours,  iii) 0.15 M I2 in 
a mixture of THF, H2O and 2,6-lutidine (4:2:1), 2.5 hours, iv) NH3, 
MeOH, 20 hours v) 80% aq. AcOH, overnight. 
3.1.3 3´,5´-Cyclic phosphate and thiophosphate esters (III) 
3´,5´-Cyclic phosphate and thiophosphate esters of antiviral nucleosides 2´-C-
methylguanosine and 2´-C,O
6
-dimethylguanosine were synthesized as potential 
prodrugs. 2´-C-Methylguanosine was prepared according to previously published 
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-Dimethylguanosine was prepared 
by using same glycosyl donor for glycosylation of 6-chloroguanine, followed by 
treatment with sodium methoxide in methanol.
135
 The amino function was 
protected with 4-methoxytrityl group to allow selective 5´-O-phosphorylation. 
The 2´-hydroxyl function of the MMTr-protected 2´-C-methyl- and 2´-C,O
6
-
dimethylguanosine did not require a protecting group. The synthetic details are 





-dimethylguanosine (27) was phosphitylated with 2-
cyanoethyl-N,N-diisopropylchlorophosphoramidite and the 3´,5´-cyclic phosphite 
structure was formed using 1H-tetrazole activation in a large volume of MeCN 
(Scheme 23). The phosphite triester was sulfurized with elemental sulfur to form 
the thiophosphate ester 28, which was obtained in low yield (16%). 2´-C,O
6
-
dimethylguanosine 3´,5´-cyclic phosphorothioate  (29) was obtained by removal 
of the 2-cyanoethyl group in a mixture of TEA and DCM and subsequent 
detritylation with 80% aqueous AcOH. 29 was treated with iodomethyl pivalate 
in MeCN and MMTr-protection was removed with 80% aqueous AcOH to obtain 
2´-C,O
6
-dimethylguanosine cyclic 3´,5´-(S-[(pivaloyl)oxy-methyl] phosphoro-
thioate)  (30) in low yield (14%). 
 
Scheme 23 Synthesis of compounds 29 and 30: i) NC(CH2)2O(iPr2N)PCl, TEA, 
DCM, 20-40 min, ii) 1H-tetrazole, MeCN, 2.5 hours,  iii) S8, Py, 
overnight, iv) TEA, DCM, 18 hours, v) 80% aq. AcOH, 5 hours, vi) 
Dowex 50WX8 Na
+
 form, H2O, vii) iodomethyl pivalate, MeCN, 2.5 
hours. 
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2´-C-Methylguanosine 3´,5´-cyclic phosphorothioate (33) was prepared using a 
somewhat different method , i. e. by sulfurizing the 3´,5´-cyclic phosphite triester 
with 3H-1,2-benzodithiol-3-one 1,1-dioxide in MeCN with slightly better yield 
(32%) (Scheme 24). The 2-cyanoethyl group was cleaved during silica gel 
purification with DCM containing 1% of TEA. Detritylation with 80% aqueous 
AcOH gave 33 as triethylammonium salt. 
To obtain 2´-C,O
6





-dimethylguanosine (27) was phosphitylated with 1-
chloro-N,N-diisopropyl-1-methoxyphosphinamine and the 3´-hydroxyl group 
was then displaced as described above  (Scheme 25). Oxidation with iodine and 
detritylation in 80% aqueous AcOH gave triester 35 in moderate yield (60%).  
 
Scheme 24 Synthesis of compound 33: i) NC(CH2)2(iPr2N)PCl, TEA, DCM, 40 min, 
  ii) 1H-tetrazole, MeCN, 3 hours,  iii) 3H-1,2-benzodithiol-3-one 1,1-
  dioxide, MeCN, overnight iv) SiO2 chromatography with 15% MeOH 
  and 0.5% TEA in DCM, v) 80% aq. AcOH. 
 
Scheme 25 Synthesis of compound 35: i) (iPr2N)MeOPCl, TEA, DCM, 30 min, ii) 
1H-tetrazole, MeCN,  2 hours,  iii) 0.15 M I2 in a mixture of THF, H2O 
and 2,6-lutidine (4:2:1),  16 hours, iv) 80% aq. AcOH, 24 hours. 
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3.1.4 4-Acetylthio-2,2-dimethyl-3-oxobutyl protected oligomeric 
phosphodiesters (IV) 
Thymidine trimer and tetramer, bearing three 4-acetylthio-2,2-dimethyl-3-
oxobutyl moieties as esterase- and thermolabile phosphodiester protecting 
groups, were synthesized. The synthesis of S-(4-hydroxy-3,3-dimethyl-2-
oxobutyl)ethanethioate has been previously published.
48
  
Nucleotide building blocks 38 and 39 for the assembly of thymidine tetramer 
were synthesized as outlined in Scheme 26. 5´-O-(4-methoxytrityl)thymidine 
(36) was phosphitylated with 1-chloro-N,N,N´,N´-tetraisopropylphosphane-
diamine and the diisopropylamino ligands were displaced in a stepwise manner 
with 3´-(tert-butyldimethylsilyl)thymidine and S-(4-hydroxy-3,3-dimethyl-2-
oxobutyl)ethanethioate in MeCN using 1H-tetrazole activation. Oxidation with 
iodine in aqueous conditions gave dimer 37 in moderate yield (54%). The tert-
butyldimethylsilyl group was removed with tetrabutylammonium fluoride to 
obtain 5´-O-(4-methoxytrityl)thymidine-3´-yl thymidine-5´-yl 4-acetylthio-2,2-
dimethyl-3-oxobutyl phosphate (38) and the 4-methoxytrityl group with 80% 
aqueous acetic acid to obtain thymidine-3´-yl 3´-O-(tert-butyldimethyl-
silyl)thymidine-5´-yl 4-acetylthio-2,2-dimethyl-3-oxobutyl phosphate (39). 
 
Scheme 26 Synthesis of compounds 38 and 39: i) (iPr2N)2PCl, TEA, DCM, 15 min, 
ii) 3´-O-TBDMS-thymidine, 1H-tetrazole, MeCN, 30 min, iii) S-(4-
hydroxy-3,3-dimethyl-2-oxobutyl)ethanethioate, 1H-tetrazole, MeCN, 70 
min, iv) 0.15 M I2 in a mixture of THF, H2O and 2,6-lutidine (4:2:1), 
overnight, v) TBAF, THF, AcOH, 4 days, vi) 80% aq. AcOH. 
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Nucleotide building blocks for the assembly of thymidine trimer were 
synthesized as illustrated in Scheme 27. 5´-O- (4-methoxytrityl)thymidine (36) 
was phosphitylated with 1-chloro-N,N-diisopropyl-1-methoxyphosphinamine and 
S-(4-hydroxy-3,3-dimethyl-2-oxobutyl)ethanethioate in MeCN was coupled 
using 1H-tetrazole activation. Oxidation with iodine in aqueous conditions gave 
nucleotide 40, which was detritylated in 80% aqueous AcOH to give 41. To form 
4-acetylthio-2,2-dimethyl-3-oxobutyl protected  dimer 43, nucleoside 36 was 
first phosphitylated with 1-chloro-N,N,N´,N´-tetraisopropyl-phosphanediamine. 
The diisopropylamino ligands were then displaced with nucleotide 41 and S-(4-
hydroxy-3,3-dimethyl-2-oxobutyl)ethanethioate using 1H-tetrazole activation 
and finally oxidized. MMTr-protection was removed with 80% aqueous AcOH. 
 
Scheme 27 Synthesis of compounds 41 and 43: i) (iPr2N)MeOPCl, TEA, DCM, 30 
min, ii) ethyl 4-(acetylthio)-2-(hydroxymethyl)-2-methyl-3-oxobutano-
ate, 1H-tetrazole, MeCN, 2 hours, iii) 0.15 M I2 in a mixture of THF, 
H2O and 2,6-lutidine (4:2:1), overnight, iv) 80% aq. AcOH, v) (iPr2)2PCl, 
TEA, DCM, 30 min, vi) compound 41, 1H-tetrazole, MeCN, 1.5 hours.  
 
The synthesis of 4-acetylthio-2,2-dimethyl-3-oxobutyl protected phosphotriester 
45 is presented in Scheme 28. 5´-O-Pivaloylthymidine (44) was first 
phosphitylated with 1-chloro-N,N,N´,N´-tetraisopropylphosphanediamine, then 
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coupled with dimer 43 and  S-(4-hydroxy-3,3-dimethyl-2-oxobutyl)ethanethioate 
and finally oxidized with iodine in aqueous conditions. 
 
Scheme 28 Synthesis of compound 45: i) (iPr2N)2PCl, TEA, DCM, 30 min, ii) 
compound 43, 1H-tetrazole, MeCN, 1.5 hours, iii) S-(4-hydroxy-3,3-
dimethyl-2-oxobutyl)ethanethioate, 1H-tetrazole, MeCN, 1.5 hours, iv) 
0.15 M I2 in a mixture of THF, H2O and 2,6-lutidine (4:2:1), overnight. 
To obtain 4-acetylthio-2,2-dimethyl-3-oxobutyl protected phosphotriester 46, the 
nucleotide building block 38 was first phosphitylated with 
tris(diethylamino)phosphine using 1H-tetrazole as activator (Scheme 29). The 
diethylamino ligands were stepwise displaced with building block 39 and S-(4-
hydroxy-3,3-dimethyl-2-oxobutyl)ethanethioate and oxidized. Desilylation with 
tetrabutylammonium fluoride and detritylation with 80% aqueous AcOH gave 
46. 
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Scheme 29 Synthesis of compound 46: i) (Et2N)3P, 1H-tetrazole, MeCN, 3 hours, ii) 
compound 39, 1H-tetrazole, MeCN, 1.5 hours, iii) S-(4-hydroxy-3,3-
dimethyl-2-oxobutyl)ethanethioate, 1H-tetrazole, MeCN, 1.5 hours, iv) 
0.15 M I2 in a mixture of THF, H2O and 2,6-lutidine (4:2:1), overnight, 
v) TBAF, THF, AcOH, 3 days, vi) 80% aq. AcOH, 22 h. 
Synthesis of 4-acetylthio-2,2-dimethyl-3-oxobutyl 5´-O-pivaloylthymidin-3´-yl 
thymidine-5´-yl phosphate (48) is outlined in Scheme 30. 5´-O-
Pivaloylthymidine (44) was phosphitylated with 1-chloro-N,N,N´,N´-
tetraisopropylphosphanediamine and the diisopropylamine groups were displaced 
with 3´-O-(4,4´-dimehoxytrityl)thymidine and   S-(4-hydroxy-3,3-dimethyl-2-
oxobutyl)ethanethioate using 1H-tetrazole activation. The oxidation of the 
phosphite triester to phosphate triester was done as above with iodine. 
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Scheme 30 Synthesis of compound 48: i) (iPr2N)2PCl, TEA, DCM, 40 min, ii) 3´-O-
(4,4´-dimethoxytrityl)thymidine, 1H-tetrazole, MeCN, 30 min, iii) S-(4-
hydroxy-3,3-dimethyl-2-oxobutyl)ethanethioate, 1H-tetrazole, MeCN, 60 
min, iv) 0.15 M I2 in a mixture of THF, H2O and 2,6-lutidine (4:2:1), 
overnight, v) 80% aq. AcOH, 4 hours. 
3.2 Kinetic studies 
The synthesized 5´,5´-phosphodiesters and esterase labile 5´,5´-phosphotriesters 
as well as the 3´,5´-cyclic phosphate and thiophosphate esters have been further 
studied by Alios BioPharma. The data is owned by the company and is not 
discussed here. Kinetic measurements for the synthesized 2,2-bissubstituted 3-
acyloxypropyl protected 5´-phosphoramidates and 4-acetylthio-2,2-dimethyl-3-
oxobutyl protected oligomeric phosphodiesters are discussed below. 
3.2.1 2,2-Bissubstituted 3-acyloxypropyl protected 5´-phosphoramidates (I) 
3.2.1.1 Chemical stability  
The non-enzymatic hydrolysis of 3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl 
substituted phosphoramidates was studied using the 2´-O-methylcytidine 
derivative 11 as a model compound. The hydrolysis reaction was followed at pH 
7.5, 9.0 and 10.0 at 37 C. The product composition of the samples taken from 
the reaction mixture at appropriate time intervals was determined by HPLC and 
mass spectrometric analysis. 
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The non-enzymatic hydrolysis begins with parallel formation of 2´-O-
methylcytidine 5´-{N-[(S)-2-methoxy-1-methyl-2-oxoethyl]phosphoramidate} 
(51) and 2´-O-methylcytidine 5´-{O-[3-acetyloxy-2,2-bis(ethoxycarbonyl)-
propyl-N-[(S)-2-hydroxy-1-methyl-2-oxoethyl]phosphoramidate} (50), as seen 
from the time-dependent product distribution obtained at pH 10.0 and 37 C 
(Figure 13). Both intermediates are then converted to 2´-O-methylcytidine 5´-{N-
[(S)-2-hydroxy-1-methyl-2-oxoethyl]phosphoramidate} (53). 














t / s  
Figure 13 Time-dependent product distribution for the non-enzymatic hydrolysis of 
11 at pH 10.0 (0.06 mol L
-1
 glycine buffer) and 37 
o
C.  () 11, () 51, 
() 50, () 53. For the structures, see Scheme 31.  
Scheme 31 represents the two most probable pathways for the non-enzymatic 
hydrolysis of 11.  The acetyl group of 3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl 
group is hydrolyzed to give 49, which is not accumulated, but is rapidly 
converted to 51 via retro-aldol condensation and subsequent elimination (see also 
Scheme 2 on page 27). The final product 53 is then obtained from 51 by 
hydrolysis of the methyl ester of the alaninyl moiety. Alternatively, the methyl 
ester of the alaninyl moiety is hydrolyzed first to give 50 and deacetylation of the 
3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl group to 52 follows. Again, 
intermediate 52 is not accumulated, but rapidly forms 53 by retro-aldol 
condensation and subsequent phosphate elimination. 
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Table 2 compiles the obtained first-order rate constants and half-lives for the 
parallel consecutive reactions. The first-order rate constant kd (= k1 + k4) for the 
disappearance of 11 was calculated by the integrated first-order rate law. Rate 
constants k1, k3, k4, and k5 were then determined from the time-dependent 
concentrations of 50 and 51 by applying the rate law of parallel consecutive first-
order reactions (equations 1 and 2).  














  (1) 














  (2) 
Rate constant k2 was obtained by removing the acetyl group of 11 with porcine 
liver esterase (PLE) prior to kinetic run and applying then the first-order rate law. 
Rate constant k6 is assumed to be approximately the same as k2, based on the 
assumption that the lack of methyl group in 52 most likely has only a minor 
effect on the rate of the elimination step.  
Table 2 First-order rate constants (k) and half-lives (τ½) for the partial reactions 
in the non-enzymatic hydrolysis of 11 to 53 at pH 7.5, 9.0 and 10.0 at 37 
C. 
































) - - 3.4 ± 0.4 8.2 h 29 ± 1 40 min 
*
 kd = k1 +k4 
For comparison, the non-enzymatic hydrolysis of the phenyl analog 6 was 
studied at pH 7.5 and 37 C. The time-dependent product distribution of the 
reaction mixture is presented in Figure 14. The first-order rate constant for the 
hydrolysis of 6 is (3.1 ± 0.1) × 10-6 s
-1
. 
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Figure 14 Time-dependent product distribution for the non-enzymatic hydrolysis of 
6 at pH 7.5 (0.06 M HEPES buffer) and 37 
o
C: () 6, () 51, () 54, 
() 53. For the structures see Scheme 32.  
The possible degradation pathways of 6 are presented in Scheme 32. Two 
parallel reactions may occur: either the methyl ester is hydrolyzed to give 54 
followed by displacement of the phenoxy group by assistance of the alanine 
carboxylate group or the hydroxide ion first displaces the phenoxy group to give 
51 and the methyl ester hydrolysis then follows to give the final product 53. The 
intermediates 51 and 54 do not accumulate significantly. Previous studies with 
the corresponding thymidine analog indicate that hydrolysis via 54 is one order 
of magnitude faster than via 51.
136
 This most likely applies to 6 too. Since the 




 at pH 9.0 
(Table 2), the rate constant k3 at 30-fold lower hydroxide ion concentration at pH 




 and hence, the hydrolysis through 
intermediate 51 is too slow to be the main reaction pathway. 
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Scheme 32 Non-enzymatic hydrolysis of 2´-O-methylcytidine 5´-{O-phenyl-N-[(S)-
2-methoxy-1-methyl-2-oxoethyl]phosphoramidate} (6). 
3.2.1.2 Enzymatic stability 
The enzymatic stability of compounds 6 and 11 was studied with PLE (26 U   
mL
-1
) in HEPES buffer at pH 7.5 and 35 ºC. The enzymatic removal of the 
protecting groups from 11 can again take place through intermediates 49 and 50 
(Figure 15 A). The predominant reaction is formation of N-[2-methoxy-1-
methyl-2-oxoethyl)phosphoramidate 51 through 49. The hydrolysis of the alanine 
ester bond to produce 50 represents about 20% of the overall disappearance of 
11. In addition, the formation of 53 is observed. The half-life for the 




]. Of the two diastereomers, 
RP-11 and SP-11, one seems to react slightly faster than the other, but which one, 
cannot be decided on the basis of the data available. The only reaction detected 




) (Figure 15 B). Thus, the conversion of 6 to 53 is an order of magnitude 
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slower than the conversion of 11 to 51. As in case of 11, the diastereomers of 6 
react at somewhat different rate. 
 
Figure 15  RP-HPLC traces for the PLE-catalyzed (26 U mL-1) hydrolysis of 11 to 
53 (A) and 6 to 53 (B) in HEPES buffer (20 mmol, pH 7.5, I = 0.1 mol L
-
1
 with NaCl) at 35 C. For the structures see Schemes 31 and 32. 
The removal of the protecting groups was also studied at a lower PLE 
concentration (1 U mL
-1
) and in prostate carcinoma cell extract (PC3) at pH 7.5 
and 35 ºC. 36% of 9a was degraded after incubation for one day at this low PLE 
concentration. With 9b, 78% of the starting material was degraded in six hours 
under similar conditions. The enzymatic removal of the 3-acetyloxymethoxy-2,2-
bis(ethoxycarbonyl)propyl protecting group from 9b is thus at least one order of 
magnitude faster than the removal of the 3-acetyloxy-2,2-bis(ethoxycarbonyl)-
propyl protecting group from 9a. In PC3 cell extract, compounds 9a and 11 
degraded at similar rate: 48% and 55% of the compounds were degraded after 
one day, respectively. 
B A 
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3.2.2 4-Acetylthio-2,2-dimethyl-3-oxobutyl protected oligomeric 
phosphodiesters (IV) 
3.2.2.1 Chemical stability 
The non-enzymatic hydrolysis of 4-acetylthio-2,2-dimethyl-3-oxobutyl protected 
oligomeric phosphotriesters 45 and 46 was followed in HEPES buffer at pH 7.5 
and 37 C (for the mechanism see Scheme 12 on page 37). The mixtures of eight 
possible RP/SP-diastereomers were fractionated by HPLC to simplify the product 
distribution. For both compounds, a fraction showing a single chromatographic 
signal was selected for the measurements. The products were identified by 
spiking with authentic samples, by HPLC/ESI-MS analysis or by collecting a 
signal and identifying it by mass analysis. No attempt was made to find out 
which of the three possible diester intermediates were accumulated in each of the 
consecutive steps (Scheme 33). 
 
Scheme 33 Deprotection of phophotiesters 45 and 46 to phosphodiesters 55 and 56 
  through intermediate mixtures I. 
 
The departure of the first 4-acetylthio-2,2-dimethyl-3-oxobutyl group from 45 
gave a mixture of diprotected intermediates I
45a
 (Reaction A in Scheme 33). The 





half-life for the next conversion to monoprotected intermediates I
45b
 (Reaction B) 




]. Removal of the third protecting group 
gave the desired final product 55 (Reaction C). The diastereomers react with 
somewhat different rates as seen from Figure 16. The removal of the last 
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protecting group from the slowest eluting isomer in intermediate mixture I
45b
 is 
slower than the removal from the two faster eluting isomers. Accordingly, the 
microenvironment seems to have some effect on the rate of the removal of the 
protecting group by cyclization.  
 
Figure 16 RP-HPLC traces for the hydrolysis of 45 to 55 in HEPES buffer (20 
mmol, pH 7.5, I = 0.1 mol L
-1
 with NaCl)) at 37 C. 





 to produce the fully deprotected final product 
56 (Scheme 33 and Figure 17). The half-lives for the disappearance of 46 and I
46a
 









respectively. More than 70% of 45 and 46 were converted to the unprotected 
phosphodiesters 55 and 56, respectively, in 4 days. In the reaction of 45, only 
small amount of side products were detected by MS analysis The identified side 
products included TpT, PivO-TpTpTp, PivO-TpTpT, PivO-TpT, PivO-Tp-
CH2C(Me2)C(O)CH2SAc. The amount of side products was somewhat more 
marked with 46, including TpT and Tp-CH2C(Me2)C(O)CH2SAc, but all of them 
were not characterized. 
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Figure 17 RP-HPLC traces for the hydrolysis of 46 to 56 in HEPES buffer (20 
mmol, pH 7.5, I = 0.1 mol L
-1
 with NaCl)) at 37 C. 
The possibility of chain cleavage by P-O bond fission at a 4-acetylthio-2,2-
dimethyl-3-oxobutyl protected phosphodiester linkage was also studied. The 
occurrence of such cleavage had been earlier detected with 4-benzoylthio-2,2-




pivaloylthymidin-3´-yl thymidine-5´-yl phosphate (48) was used as a model 
compound. Figure 18 shows that although the formation 5´-O-
pivaloylthymidylyl-3´,5´-thymidine (Piv-TpT) was the predominant reaction, 
also thymidine and 5´-O-pivaloylthymidine (44) were formed. These two 
compounds constituted about 9% of the final products. The signal at 20.2 min 
most likely refer to 5´-(4-acetylthio-2,2-dimethyl-3-oxobutyl)phosphate and 5´-
pivaloylthymidine 3´-(4-acetylthio-2,2-dimethyl-3-oxobutyl)phosphate, but this 
could not be verified by MS. The half-lives for the disappearance of the 




] and 10.2 h [k = (1.88 
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Figure 18  RP-HPLC traces for the hydrolysis of 48 in HEPES buffer (20 mmol, pH 
7.5, I = 0.1 mol L
-1
 with NaCl)) at 37 C. 
3.2.2.2 Enzymatic stability 
To study the enzymatic stability of phosphotriesters 45 and 46, the removal of 4-
acetylthio-2,2-dimethyl-3-oxobutyl group was followed in the presence of 
porcine liver esterase (2.6 U mL
-1
) in HEPES buffer at pH 7.5 and 37 C (Figures 
19 and 20). Phosphotriester 45 was converted to phosphodiester 55 in two days. 





]. The identified side products included TpTpMe, pTpTpMe and PivO-TpT. The 
enzymatically activated deprotection most likely proceeds through deacetylated 
intermediates, but these did not accumulate. An interchain disulfide bond 
formation competed as side reaction with the chemical removal of the remnants 
of the protecting group, lending support for the formation of deacetylated 
intermediates. The S-S bond mediated dimerization was observed with both 
phosphotriesters. The conversion of 46 to 56 proceeds as with 45, but it is 
somewhat slower. The half-life for the disappearance of 46 was 36 minutes [k = 




] and the deprotection to 56 was not complete even after 5 
days. A considerable amount of an unknown byproduct was formed at tR = 12.8 
(Figure 20). The deprotection of dimer 48 produced 5´-O-pivaloylthymidylyl-
3´,5´-thymidine quantitatively. The half-lives for the enzymatic deacetylation of 
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Figure 19 RP-HPLC traces for the enzymatic hydrolysis of 45 to 55 in PLE (2.6 U 
mL
-1
) containing HEPES buffer (20 mmol, pH 7.5, I = 0.1 mol L
-1
 with 
NaCl)) at 37 C. Signals marked with X refer to disulfide products. 
 
 
Figure 20 RP-HPLC traces for the enzymatic hydrolysis of 46 to 56 in PLE (2.6 U 
mL
-1
) containing HEPES buffer (20 mmol, pH 7.5, I = 0.1 mol L
-1
 with 
NaCl) at 37 C. Signals marked with X refer to disulfide products.
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4 DISCUSSION 
4.1 Background 








 groups. The removal of the 
protecting groups is triggered by carboxyesterase activity. With the 3-acetyloxy-
2,2-bis(ethoxycarbonyl)group, the remnant of the enzymatically deacetylated 
group is removed by retro-aldol condensation and subsequent elimination (see 
Scheme 2).
 
With its 3-acetyloxymethoxy analog, hydrolytic removal of the 
hydroxymethyl group precedes the retro-aldol condensation.
 
The removal rate of 
these protecting groups can be altered in two ways.
137
  Firstly, the nature of the 
acyl group determines the rate of the enzymatic deprotection step: bulky acyl 
groups are removed slower than simple ones. The stability of the deacylated 
product may, in turn, be tuned by the polarity of the substituents at C2: 
substituents that allow charge delocalization facilitate the departure of the 
protecting group. In case the chemical removal is considerably slower than the 
enzymatic deacylation, doubly protected monophosphate group may become 
fully deacylated before the departure of the remnants of either group. This helps 
to avoid the inhibition of enzymatic deacylation by accumulation of negative 
charge on the phosphate. 
Another useful feature of the 3-acetyloxy- and 3-acetyloxymethoxy-
bis(ethoxycarbonyl)propyl groups is that conjugate groups aimed at targeting the 
prodrug to a certain cell type or enhancing cellular uptake may be attached to C2 
by ester or amide linkages without interfering with the retro-aldol condensation. 
The drawback of these groups is that they, upon deprotection, produce enones 




The enzymatic deacetylation of 4-acetylthio-2,2-dimethyl-3-oxobutyl group is, in 
turn, followed by intramolecular attack of the exposed mercapto group on C1 of 
the group, resulting in departure by cyclization. The group is not only esterase 
labile but additionally thermally removable at 37 C.
48
 In case the enzymatic 
deprotection slows down, the protecting group is released by intramolecular 
cyclization to a substituted tetrahydrothiophenone.
 
As mentioned above, the rate 
of this process may be tuned by the electronegativity of the 2-substituents. This 
enzyme-independent removal plays a role with oligophosphate compounds, since 
it is known that the removal of esterase labile protecting groups significantly 
slows down, if there is negative charge present close to the enzyme cleavage 
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site.
53
 These groups should not suffer from toxicity problems, since they are 





Potential nucleoside monophosphate prodrugs of antiviral nucleosides bearing 
either 3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl or 3-acetyloxymethoxy -2,2-
bis(ethoxycarbonyl)propyl group, as well as oligomeric thymidine 
phosphodiesters with multiple 4-acetylthio-2,2-dimethyl-3-oxobutyl protecting 
groups, were synthesized. To obtain the appropriately protected nucleosides for 
the synthesis of the desired final products, conventional nucleic acid protecting 
group chemistry was applied. Amino functions of nucleobases were protected 
with MMTr-group by using TBDMS-group as transient 5´-O-protection or by 
persilylating the hydroxyl functions with trimethylsilyl group (TMS). MMTr-
group was additionally used as transient 5´-O-protection. 2´- and 3´-OH groups 
were protected with Lev-, Bz-, DMTr- or TBDMS-groups, when needed. The 
synthesis carried out in this thesis proceeded mainly well with good to moderate 
yields, but few considerations are worth mentioning. 
4.2.1 2,2-Bissubstituted 3-acyloxypropyl protected 5´-phosphoramidates (I) 
Two antiviral nucleosides, ribavirin and 2´-O-methylcytidine, were converted to 
their 3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl and  3-acetyloxymethoxy-2,2-
bis(ethoxycarbonyl)propyl  protected 5´-phosphoramidates derived from L-
alanine methyl ester. Usually potentially toxic phenyl and naphthyl groups are 
used to this purpose.
77, 139
 The removal is initiated by enzymatic hydrolysis of the 
alaninyl ester linkage, followed by intramolecular displacement of the aryloxy 
group (see Scheme 9). In our approach, the O-protecting group is removed first, 
leaving the alaninyl group esterified. In both cases, the final conversion to 5´-
monophosphate depends on phosphoramidase activity. The synthesis of the 
desired final products proceeded well with good to moderate yields. The phenyl 
compounds were obtained by reacting the protected nucleoside with 
diphenylphosphite followed by oxidative amination with L-alanine methyl ester. 
The phosphoramidates bearing the 2,2-bissubstituted 3-acetyloxypropyl and 3-
acetyloxymethoxypropyl protecting groups were obtained by reacting the 
protecting group alcohol with diphenylphosphite. The phenol was displaced from 
the obtained H-phosphonate with the appropriately protected nucleoside and 
oxidative amination with L-alanine methyl ester followed. 
 Discussion 69 
4.2.2 5´,5´-phosphodiesters and 3-acetyloxymethoxy-2,2-bis(ethoxycarbo-
nyl)propyl and pivaloyloxymethyl protected 5´,5´-phosphodiesters (II) 
The 3-acetyloxymethoxy-2,2-bis(ethoxycarbonyl)propyl group was additionally 
studied as the phosphate protecting group of 5´,5´-phosphodiesters. After 
removal of the protecting group by carboxyesterases, the released 5´,5´-
phosphodiester is thought to be cleaved to a nucleoside and a nucleoside 
monophosphate by phosphodiesterases. The 2´-C-methyl derivatives of 
adenosine, guanosine and uridine have shown antiviral activity against HCV and 
were chosen for the synthesis. These nucleosides were converted to 5´,5´-diesters 
containing two similar or dissimilar nucleosides, and the 2´-C-methyladenosine 
5´,5´-diester was protected with pivaloyloxy-carbonyl and  3-acetyloxymethoxy-
2,2-bis(ethoxycarbonyl)propyl groups. 
The protection of the tertiary 2´-OH of purine nucleosides that were used as 
building blocks in the synthesis of 5´,5´-phosphodi- and triesters was not 
straightforward. To obtain 2´,3´-di-O-levulinoyl-N
6
-(4-methoxytrityl)-2´-C-
methyladenosine (12), the levulinoylation with an excess of levulinic anhydride 
had to be done twice. The first levulinoylation in a mixture dioxane and pyridine 
yielded the mono levulinoylated product, but also a trace amount of 12 was 
obtained. The second levulinoylation of this mixture in DCM using DMAP as 
catalyst yielded the desired product. In case of benzoyl protection, 2.5 
equivalents of benzoyl chloride in the reaction did not yield the di-benzoylated 
2´-C-methylguanosine. However, both the 2´- and 3´-OH groups were protected 
with same amount of benzoylchloride in the reaction with 2´-C-methyluridine. 
The lower reactivity of the tertiary 2´-OH of purine nucleosides may, at least in 
the case of 2´-C-methylguanosine, result from rise in steric hindrance caused by 
the MMTr-protection of the base moiety. When removing the transient TBDMS-
protection, acetic acid was added to the reaction mixture in order to reduce 
basicity of TBAF and prevent premature removal of the levulinoyl groups.
140
 
This reaction proceeds fairly slowly. 
Marked tailing severely complicated the purifications of 5´,5´-diesters 14 and 22 
and 5´,5´-triester 20, the 2´-C-guanosine derivatives in particular, and largely for 
this reason the yields of these compounds remained low. In addition, the yield of 
compound 15 was low due to the difficulties in introducing the 
pivaloyloxymethyl protection. The reaction of compound 13 with chloromethyl 
pivalate was pursued in different solvents including MeCN, dioxane and N-
methyl-2-pyrrolidone (NMP) at room temperature or by heating or refluxing the 
reaction mixture. The best results were obtained in a mixture of NMP and TEA 
and heating the reaction mixture at 60 °C for four days,
141
 but still with a poor 
yield (15%).  
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4.2.3 3´,5´-Cyclic phosphate and thiophosphate esters (III) 
3´,5´-Cyclic nucleoside monophosphates have more recently been used for the 
delivery of nucleoside monophosphates. Removal of the protecting group 
releases a 3´,5´-cyclic phosphodiester which is expectedly cleaved to the 
nucleoside 5´-monophosphate by 3',5'-cyclic nucleotide phosphodiesterases. 2´-
C-methylguanosine and 2´-C,O
2
-dimethylguanosine, which show antiviral 
activity against HCV, were chosen for the synthesis of their 3´,5´-
phosphorothioates. The latter was additionally transformed to S-
pivaloyloxymethyl triester. 
The appropriately protected nucleoside was first phosphitylated to 
phosphoramidate, which was then coupled to 3´,5´-cyclic structure with 1H-
tetrazole as activator in a large volume of MeCN and oxidation or sulphurization 
followed. The formation of the 3´,5´-cyclic structures that still bore the MMTr-
group as amino protecting group were obtained at low yields. The sulfurization 





dimethylguanosine with elemental sulfur gave the desired product in 16% yield. 
Somewhat better yield (32%) was obtained for the sulfurization of the N
2
-(4-
methoxytrityl)-2´-C-methylguanosine derivative with 3H-1,2-benzodithiol-3-one 
1,1-dioxide (Beaucage reagent). The 3´,5´-cyclic methyl phosphate triester 35 
was obtained in similar yield (30%) by oxidation with aqueous iodine. The 
introduction of the pivaloyloxymethyl group to the 3´,5´-cyclic phosphorothioate 
as iodomethyl pivalate turned out to be inefficient with only 14% total yield. 
Introduction of the enzymatically and thermally removable 4-acetylthio-2,2-
dimethyl-3-oxobutyl protection to 3´,5´-cyclic nucleoside monophosphates was 
attempted by phosphoramidate method. Bis(diisopropyl-amino)chlorophosphine 
was used as phosphitylating agent, but the synthesis failed. No cyclization took 
place. In addition, the synthesis was attempted with enzymatically and thermally 
removable 2-ethoxycarbonyl-2-methyl-3-oxo-4-pivaloylthiobutyl group by using 
bis(diisopropylamino)chlorophosphine or bis(diethylamino)chlorophosphine as 
phosphitylating agent, but again unsuccessfully.  The 3´,5´-cyclic 
monophosphate should give two 
31
P NMR signals at about 6 to 7 ppm difference, 
referring to the cis- and trans-conformers of the 3´,5´-cyclic phosphite.
142
 The 
successful 3´,5´-cyclization reactions that resulted compounds 28, 31, and 34 
showed peaks at about 123 and 129 ppm.  In contrast, only one peak at about 115 
ppm was observed. The 4-acetylthio-2,2-dimethyl-3-oxobutyl protecting group 
has, however, been later introduced to the 3´,5´-cyclic monophosphate by 
applying the recently published method, where the 3´,5´-cyclic structure was 
generated from a nucleoside 3´-H-phosphonate by intramolecular cyclization 
using pivaloylchloride as an activator in a mixture of DCM and pyridine (95:5) at 
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0 ºC.
143
 The resulting 3´,5´-cyclic H-phosphonate diester was then further 
oxidized to iodophosphate and the iodine was replaced with S-(4-hydroxy-3,3-
dimethyl-2-oxobutyl)ethanethioate to obtain 4-acetylthio-2,2-dimethyl-3-
oxobutyl protected 3´,5´-cyclic nucleoside triester.
144
 
4.2.4 4-Acetylthio-2,2-dimethyl-3-oxobutyl protected oligomeric 
phosphodiesters (IV) 
The 4-acetylthio-2,2-dimethyl-3-oxobutyl group was studied as protecting group 
of oligomeric phosphodiesters to find out the enzymatical and thermal 
degradation properties in molecules containing more than one such protecting 
group. The synthesis of the building blocks for the assembly of the thymidine 
derived trimer 45 and tetramer 46 proceeded with good to moderate yields. The 
low overall yields of the final compounds 45 and 46 (4.9% and 1.8%, 
respectively) result mainly from the difficulties in purification, which arise from 
the low polar nature of the compounds. The small amounts of 45 and 46 did not 
enable the separation of RP- and SP-diastereomers. The RP/SP-mixtures were only 
fractionated and a fraction showing a single chromatographic signal was used in 
the kinetic measurements. If the trimer and tetramer were synthesized on solid 
support, the yields might be better and especially the purification might be 
simpler. However, the conventional solid phase methods are not suitable with 
phosphate protecting groups which are base labile and leave readily by 
intramolecular cyclization. The development of solid phase procedures was not 
the object of this work. 
4.3 Kinetic studies 
4.3.1 2,2-Bissubstituted 3-acyloxypropyl protected 5´-phosphoramidates (I) 
Treatment of 3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl and 3-acetyloxy-
methoxy-2,2-bis(ethoxycarbonyl)propyl protected nucleoside phosphoramidates 
with PLE or PC3 cell extract resulted in the removal of the protecting groups and 
release of the phosphoramidate monoanion. These protecting groups have been 
previously studied as bis-protected derivatives of nucleoside 5´-
monophosphates.
47
  With the 3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl group, 
the deacetylation of the diester obtained by removal of the first protecting group 
was significantly slower (τ½ = 150 h) than the initial deacetylation (τ½ = 194 s). 
The additional CH2O-group of 3-acetyloxymethoxy-2,2-bis(ethoxycarbonyl)-
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propyl protection accelerated the initial deacetylation of the phosphotriester 20-
fold (τ½ =  10 s) and, more importantly, the deacetylation of the monoanionic 
phosphodiester more than 50-fold (τ½ = 2.7 h). The negative charge on the 
substrate somehow prevented proper action of carboxyesterases, but the 
additional CH2O-group brought the enzyme cleavage site a bit further from the 
negative charge of the phosphodiester intermediate.  
The same observation was done with phosphoramidates 9a and 9b. When the 
compounds were treated with PLE at low enzyme concentration (1 U mL
-1
), 9b 
bearing a 3-acetyloxymethoxy-2,2-bis-(ethoxycarbonyl)propyl group was 
deacetylated one order of magnitude faster than 9a. The enzymatic hydrolysis of 
3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl group from 11 is relatively slow and 
the hydrolysis of alanine methyl ester linkage competes representing 20% of the 
overall disappearance of 11. With 3-acetyloxymethoxy-2,2-bis(ethoxycarbonyl)-
propyl protection this is not observed, since the enzymatic reaction is faster. The 
enzymatic hydrolysis of the phenyl analog 6 is very slow, one order of magnitude 
slower than the hydrolysis of 11. Table 3 summarizes the obtained reaction rate 
constants and half-lives for the disappearance of compounds 6 and 11.  
Table 3 Obtained reaction rate constants (k) and half-lives (τ½) for the 
disappearance of compounds 6 and 11 in the presence (26 U mL
-1 
of 
PLE) and absence of enzyme. 
Compound k (PLE) / s
-1
 τ½ (PLE)      k  / s
-1
  τ½  
6  (4.5 ± 0.4) × 10
-6
 43 h      (3.1 ± 0.1) × 10
-6
   62 h 
11 (3.4 ± 0.2) × 10
-5
 5.7 h (0.32 ± 0.02) × 10
-5
  60 h 
4.3.2 4-Acetylthio-2,2-dimethyl-3-oxobutyl protected oligomeric 
phosphodiesters (IV) 
The 4-acetylthio-2,2-dimethyl-3-oxobutyl groups were released from the 
oligomeric thymidine model compounds, 45 and 46, both enzymatically and 
thermally. The reaction rate constants and half-lives for the non-enzymatic 
removal of 4-acetylthio-2,2-dimethyl-3-oxobutyl group from 45, 46 and 48 
(Table 4) are of the same order of magnitude as previously reported for 2´,3´-O-
isopropylideneuridine 5´-(methyl 4-acetylthio-2,2-dimethyl-3-oxobutyl) 
phosphate and 4-acetylthio-2,2-dimethyl-3oxobutyl bis(2´-C-methyluridin-5´-yl) 
phosphate under the same conditions (τ½ = 11.2 h and τ½ = 6.9 h, respectively).
48
 





 occurred at comparable rate too (Table 4). The rate of the enzymatic 
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deacylation of 2´,3´-O-isopropylideneuridine 5´-(methyl 4-acetylthio-2,2-
dimethyl-3-oxobutyl) phosphate (τ½ = 4.7 min)
48
 is also consistent with the rates 
obtained for compounds 45, 46 and 48. The hydrolysis of 4-acetylthio-2,2-
dimethyl-3-oxobutyl group has been reported to occur at comparable rate also as 
protecting group of thymidine 3´,5´-cyclic monophosphate under similar 




Table 4  Obtained reaction rate constants (k) and half-lives (τ½) for the 





 in the presence (2.6 U mL
-1 
of PLE) and absence of 
enzyme.  
Compound k (PLE) / s
-1
 τ½ (PLE)      k  / s
-1
  τ½  
45 (4.3 ± 0.3) × 10
-3
  2.7 min    (2.5 ± 0.1) × 10
-5
   7.8 h 
I
45a - -    (1.8 ± 0.2) × 10
-5
 10.7 h 
46 (3.2 ± 0.1) × 10
-4
 36 min   (3.1 ± 0.2) × 10
-5
   6.2 h 
I
46a
 - -   (2.7 ± 1.0) × 10
-5
   7.2 h 
48
a 
(9.5 ± 0.5) × 10
-3
 1.2 min    (1.94 ± 0.02) × 10
-5
   9.9 h 
48
b 
(6.7 ± 0.6) × 10
-3
 1.7 min    (1.88 ± 0.03) × 10
-5
 10.2 h 
a
 slower eluting diastereomer 
b
 faster eluting diastereomer 
The enzymatic hydrolysis of 4-acetylthio-2,2-dimethyl-3oxobutyl bis(2´-C-
methyluridin-5´-yl) phosphate, however, is somewhat slower (τ½ = 83 min) than 
the deacylation of compounds 45, 46 and 48. For some reason, the protecting 
group seems to be more available for the deacylation by the enzyme in the 
oligomeric structures than in the 5´,5´-phosphodiester. Interestingly, also in case 
of 3´,5´-cyclic monophosphates, the enzymatic removal of 3-acetyloxy-2,2-
bis(ethoxycarbonyl)propyl group from 2´-C-methyluridine derivative was 
markedly slower (τ½ = 35 h) than from thymidine derivative (τ½ = 93 min).
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The additional steric hindrance of 2´-methyl group in the already more crowded 
2´-position of the ribose sugar most likely has a retarding effect on the reaction 
rate.  
A side reaction of internucleosidic P-O bond cleavage was observed, when the 
non-enzymatic removal of 4-acetylthio-2,2-dimethyl-3-oxobutyl group from 5´-
O-pivaloylthymidin-3´-yl thymidine-5´-yl phosphate was studied. The side 
reaction represents about 9% of the total disappearance of the starting material 48 
and is about the same magnitude as previously described for the thermally 
removable 4-benzoylthio-2,2-dimethyl-3-oxobutyl and 2-ethoxycarbonyl-2-
methyl-3-oxo-4-pivaloylthiobutyl groups (15% and 5%, respectively).
48
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Although the side reaction is rather marked with 48, it is not much increased with 
oligomer 45 which is protected with three 4-acetylthio-2,2-dimethyl-3-oxobutyl 
groups. The competing chain cleavage starts to play a role only when the 
enzymatic removal becomes so slow that the protecting groups are removed non-
enzymatically.  
The non-enzymatic departure of 4-acetylthio-2,2-dimethyl-3-oxobutyl groups 
from the oligomeric phosphotriesters 45 and 46 most likely occur as described 
earlier.
48
 Hydration of the 3-oxo group forms a geminal diol, which allows the 
acetyl migration from the sulfur atom and the exposed mercapto group then 
attacks C1 releasing the protecting group as 4,4-dimethyl-3-acetyloxy-4,5-
dihydrothiophene (Reaction A, Scheme 34). After hydration of the 3-oxo group, 
the competing side reaction can occur by intramolecular attack of an oxyanion at 
the phosphorus atom (Reaction B, Scheme 34). 
 
Scheme 34 Mechanism of non-enzymatic removal of 4-acetylthio-2,2-dimethyl-3-
oxobutyl protecting group (reaction A) and the observed side reaction of 
P-O3´/P-O5´ bond cleavage (reaction B).  
4.4 Conclusions 
This thesis includes studies on the feasibility of 3-acetyloxy-2,2-
bis(ethoxycarbonyl)propyl, 3-acetyloxymethoxy-2,2-bis(ethoxycarbonyl)propyl 
and 4-acetylthio-2,2-dimethyl-3-oxobutyl groups as phosphate protecting groups. 
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All of the protecting groups were shown to undergo conversion to fully 
deprotected products in the presence of carboxyesterase. The enzymatical 
removal of 3-acetyloxymethoxy-2,2-bis(ethoxycarbonyl)propyl group from 
nucleoside 5´-phosphoramidate was at least one order of magnitude faster than 
the removal of 3-acetyloxy-2,2-bis(ethoxycarbonyl)propyl group, thus making it 
more potential biodegradable phosphate protecting group, but the removal rate is 
nevertheless rather slow.   
Of the three studied phosphate protecting groups, the 4-acetylthio-2,2-
dimethylbutyl group seems most attractive. The weakness of prodrug strategies 
based on enzymatically removable protecting groups is that many unpredictable 
issues may have an effect on the enzymatic activity. In addition to the problem of 
negative charge disturbing the catalytic site of the enzyme, differences between 
individuals affect the enzymatic activity, including genetic polymorphism, age-
related differences in physiological conditions and drug interactions.
145
 The 
behavior and release of chemically removable protecting groups is more 
predictable. The problem with the chemically removable groups, on the other 
hand, is how to control the release of the protecting group and make difference 
between the target site and the rest of the body. With enzymatically removable 
protecting groups that are additionally thermally removable, the feature of two 
release mechanisms allows controlled removal of the protecting groups and, in 
case the enzymatic reaction becomes too slow, the thermolability ensures the 
removal of the protecting group. In addition, the five-membered byproducts that 
are released from the enzymatically and thermally removable protecting groups 
do not appear toxic, unlike the enones released from the esterase labile protecting 
groups. 
The 4-acetylthio-2,2-dimethyl-3-oxobutyl group show encouraging results as 
phosphate protecting group of oligomeric phosphodiesters. The protecting groups 
were cleaved from the studied oligomeric phosphodiesters enzymatically and 
were additionally cleavable non-enzymatically. The carboxyesterase catalyzed 
removal of the protecting group proceeded readily. Accumulation of the negative 
charge on the intermediates did not markedly retard the non-enzymatic removal 
of the protecting group. However, the rate of the thermal removal still is too slow 
to allow efficient protection of longer oligonucleotides and needs optimization. 
By increasing the electronegativity of substituents at C2, the thermal stability 
may be decreased. For instance, the replacement of one of the methyl 




The side reaction of chain cleavage, which occurred with oligomeric 
phosphodiesters protected with 4-acetylthio-2,2-dimethyl-3-oxobutyl group, 
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should be avoided. This too could possibly be achieved by increasing the 
electronegativity of substituents at C2 and, hence, making the protecting group a 
better leaving group. Furthermore, the substituents at C2 should not cause steric 
hindrance in order to allow efficient intramolecular attack of the mercapto group 
to C1 and formation of the cyclic by-product. In addition, the acyl migration 
should occur so fast that the intramolecular attack of the oxyanion cannot take 
place. The rate of the acyl migration can be influenced by steric effects: bulky 
acyl groups migrate slower than simple ones. However, the 4-acetylthio-2,2-
dimethyl-3-oxobutyl group already employs a simple acetyl group. 
Indeed, the side reaction did not occur with 4-acetylthio-2-ethoxycarbonyl-2-
methyl-3-oxobutyl group protected 3´-O-levulinoylthymidine 5´-methylphos-
phate.
48
  The protecting group was readily cleaved both enzymatically and non-
enzymatically with half-lives of 2.9 min and 34 min, respectively. Hence, by 
employing the 4-acetylthio-2-ethoxycarbonyl-2-methyl-3-oxobutyl group as 
phosphate protecting group of oligomeric phosphodiesters (Figure 21) instead of 
4-acetylthio-2,2-dimethyl-3-oxobutyl group, both the side reaction and the 
problem of too slow non-enzymatic removal could possibly be avoided.  
 
Figure 21 4-Acetylthio-2-ethoxycarbonyl-2-methyl-3-oxobutyl group as protecting 
group of phosphodiester bond. 
 
 Experimental 77 
5 EXPERIMENTAL 
More detailed information about the synthesis, kinetic measurements and 
characterizations of the discussed compounds is found in chapter Results and in 
the original publications (papers I-IV).  
5.1 Characterization of the synthesized compounds 




C NMR and 
high resolution mass spectrometric methods and with 
31
P NMR when applicable. 
2D NMR spectra (DQF-COSY, HSQC, HMBC) were used for peak assignment. 
The NMR spectra were recorded on a Bruker Avance 400, 500 or 600 NMR 
spectrometers equipped with a BBI or BBO-5mm-Zgrad probes. The operating 
frequencies were: 400 MHz, 500 MHz or 600 MHz for 
1
H; 101 MHz, 126 MHz 
or 151 MHz for 
13
C; 162 MHz, 202 MHz or 243 MHz for 
31
P, respectively. The 
chemical shifts (δ) are given in parts per million (ppm) and the coupling 
constants (J) in hertz (Hz). The exact masses (m/z) of the synthesized compounds 
were determined on Bruker Daltonics microTOF-Q mass spectrometer equipped 
with an ESI source. 
31
P NMR was also used to monitor the progress of the 
separate reaction steps in the phosphorylation reactions by acquiring a 
31
P NMR 
spectrum of a sample from the reaction mixture. The 
31
P NMR signals of the 
products in each step occur at characteristic frequencies. 
5.2 Kinetic measurements 
The kinetic measurements were carried out in sealed tubes on a thermostated 
water bath in HEPES buffer at pH 7.5 [0.02 mol L
-1
 at (35.0 ± 0.1) °C and 0.06 
mol L
-1
 at (37.0 ± 0.1) °C] or in glycine buffer at pH 9 and 10 [0.06 mol L
-1
, 
(37.0± 0.1) °C]. The ionic strength was adjusted to 0.1 mol L
-1 
with NaCl.  The 
initial substrate concentration was 0.10 mmol L
-1
 (paper I) or 0.15 mmol L
-1
 
(paper IV). The enzymatic hydrolysis was carried out in PLE concentrations 1 U 
mL
-1
 and 26 U mL
-1 
(paper I) and 2.6 U mL
-1
 (paper IV). In addition, the 
enzymatic hydrolysis was studied in a 1:2 mixture of human prostate carcinoma 
(PC3) cell extract and HEPES buffer (paper I).  Samples were taken from the 
reaction mixture at different time intervals and made acidic (pH 2) with aqueous 
hydrogen chloride and cooled on an ice-bath to stop the reaction. Samples 
containing PLE or PC3 cell extract were filtered with 0.2 µm SPARTAN 13A 
filters (paper I) or 0.2 µm RC4 syringe (paper IV). The product composition of 
the samples was analyzed by HPLC using Thermo Scientific ODS Hypersil C18 
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column [4 × 250 mm, 5 µm (paper I) and 4 × 260 mm, 5 µm (paper IV)] and a 
mixture of acetic acid/sodium acetate buffer (0.045/0.015 mol L
-1
) and 
acetonitrile, containing ammonium chloride (0.1 mol L
-1
). Signals were recorded 
on a UV-detector at a wavelength of 220 (ribavirin derivatives) or 267 nm. The 
products were identified by HPLC-ESI-MS methods on Perkin-Elmer Sciex-API-
365 triple-quadrupole spectrometer and Phenomenex Gemini C18 column (2.5 × 
150 mm, 5 µm) eluting with a mixture of water and MeCN containing 0.1% 
formic acid, spiking with authentic samples or by isolating and analyzing a peak 
by MS.  
First-order rate constants were calculated by applying the integrated first-order 
rate equation to the time-dependent diminution of the concentration of the 
starting material. The first-order rate constants for the disappearance of 
intermediates were obtained by least-squares fitting of the time-dependent 
concentration of the compounds with the rate law of two consecutive first-order 
reactions.  
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